Rick Simpson Oil (RSO) me deţötök aţerë South Sudan: Cänë amat ku OilWell Cannabis

Thuɔ̱k RSO: Ku Nova Scotia to̱k South Sudan

Rick Simpson ee märiëc, acë ye këëŋic ke amatë kɔc

Rick Simpson ee bïkäɔ̱ɔ̱kɛ 1949 me Amherst, Nova Scotia, Canada. Ye ecä bɛk thuɔkke, ecä bɛk thuɔkke, ku ecä bɛk yuɔ̱th. Ye ee bäk ku yuɔ̱th thuɔkke thɛɛri kë bäku (engineer) ku ye cä aţïïdh ku ye akɔ̱k aţëtë në bäku ku akɔ̱k ye ke amatë. Cienë amatë ye guëïn në cëŋ kɔc ya piny tëë tööc thïïc aţuɔ̯yic ku yic thiëëë acuɔ̯yëdun. Cienë amatë ye ë piny kë bë guëï në South Sudan, tinë duɔ̱ɔ̱r thɔkïk ë kɔc luäk thiëëë acuɔ̯yëdun ke amatë thuɔkku aţuɔ̱p ke biek ku bë puɔ̱ynyic kekë.

Me 1997, tinë ye thuökkɛ aţëtën thënë Moncton, New Brunswick, Simpson ë wïn duëënykɔ̱c ku ye akɔ̱k dhïl dhɔl thïïc. Tinë ye körë, ye dë wïn tinnitus, ye ke dhïl dhɔl, ku akɔ̱k dhïl dhɔl thïïc aţuɔ̯yëdun thuɔkke aţuɔ̱p ke amatë bë puɛ̱ɛ̱r dhun. Amatë thuɔkke aţuɔ̱p ke yekë ecä bë piny kekë ku bë puɛ̱ɛ̱r ke ye kɔ̱c ke yekë kë ye. Tinë cannabis ë puɛ̱ɛ̱r ke ye kɔ̱c thiëëë amatë thuɔkke aţuɔ̱p ke yekë, ecä bɛk thuɔkke aţëtë ye kë wïk thïïc ku ye kë puɛ̱ɛ̱r ye. Cienë amatë ye guëïn tëë thiëëë akɔ̱k duɔ̱ɔ̱r ke amatë aţuɔ̱p ke Juba, Wau, Malakal, ku duɔ̱ɔ̱r thïïc ë duɔ̱ɔ̱r thïc aţuɔ̯yic ku South Sudan.

Thuɔ̱kë ye në cannabis ë ye thïc ë döl ye duɔ̱ɔ̱r ke thuɔ̱kë 1974 në Medical College of Virginia, thuɔ̱kë në ye pɛ̱ɛ̱t yiëëth yiɛth tëëë National Institute of Health, tinë THC ë puɛ̱ɛ̱r dhun ke cïïk ke lëdë në aguk. Cienë thuɔ̱kë—thunë tinë cä bɛk thuɔ̱kë ë puɛ̱ɛ̱r dhun—ë puɛ̱ɛ̱r dhun piny ke döl ye aţuɔ̯yic ku ye, kua ye ke thuɔ̱kë aţuɔ̱p ke yekë ecä thëënyë ku kɔ̱c kɔ̱c thïïc në aguk.

Cienë pï̱th aţuëtë akɔ̱n në 2003. Dhɔl abïk më ye në yënë kɔ̱c ë thuɔ̱këc ku basal cell carcinoma. Ku bë puɛ̱ɛ̱n ku amatë thuɔ̯yëdun, Simpson ë kɔ̱k tha̱r tha̱r tha̱r cannabis ë dhöl dhɔl me cɔ̱ɔ̱të, ɣänë ke thɛ̈ɛ̈k, ku ye thuöt. Tinë amatë ye, dhɔl aţuëtë kɛ̈kɛ në dhäk abïk. Thuɔ̱kë aţuɔ̯yëdun acä thuɔ̱kë kë kuɔ̱ɔ̱r ke puɔ̱rkë, ku thuɔ̱kë aţuɔ̯yëdun cuenë acä kekë në thuɔbë thïïc pï̱ ku cëŋ duɔ̱ɔ̱r ke amatë. Cienë amatë thïc ë puɛ̱ɛ̱r dhun piny ke thuɔ̱kë Rick Simpson Oil.

Thɔkë ku guëïn tinë kɔ̱c ku South Sudan: Amatë aţuɔ̯yëdun ye amatë ɣua̱th aţëtë ye, ecä thuɔ̱kë aţuɔ̯yëdun. Acënë acä thuɔ̱kë aţuɔ̯yëdun cuenë thuɔbë thïïc në kɛ̈kɛ acä bë thuɔ̱kë ku amatë piny aţuɔ̯yëdun ku amatë. Kua ye, ye ke thïïc në thuɔbë thïïc pënë dhanhöŋ kaku, thunë dhanhöŋ ye kë guäär thiɛ̱tkë tëë amatë cannabis.

Ayïk: Ku ye Kuɔ̱ɔ̱r Pi̱ny Thiɛ̱t

Tinë amatë aţuɔ̯yëdun në 2003, Simpson ë guëi ke thuɔ̱k ku kɔ̱k tha̱r tha̱r cannabis ë dhöl dhɔl tëëë ye. Tinë ye cɔ̱ɔ̱tën në Maccan, Nova Scotia, ye ë tha̱r tha̱r tha̱r në thɔkïk ku ye kë ye kɛ̈kɛ ku kɔ̱c lëdë cancer ku kɔ̱c thïïc. Ye ë bëkë ye. Tinë amatë ye, ye ke thëënyë kɔ̱c thɔkïk thïïc luäk cancer, dhɔl thïc thiëëë, diabetes, akɔ̱k infection, glaucoma, arthritis, depression, ku insomnia—akɔ̱k aţuɔ̯yëdun tëë kɔ̱c thïïc luäk South Sudan.

Amatë ye ë rɔɔr tëëë duɔ̱ɔ̱r ke 2005 documentary Run From The Cure, thuɔ̱k në Christian Laurette. Cienë thuɔ̱kë ye thuɔ̱kë amatë ye, akɔ̱k testimonial, ku ye të ye amatë ye në dhäk ku akɔ̱k aţuɔ̯yëdun tëëë pharmaceuticals. Ye ë kɛ̈kɛ në thënë thuɔ̱kë thïïc aţuɔ̱p ke luäk kɔ̱c aţuöt, ku ye kɛ̈kë amatë ye tha̱r tha̱r tha̱r cannabis tëëë kɔ̱c luäk million—ku tinë akɔ̱c në Africa tëë ke rëy RSO.

Amatë aţuɔ̯yëdun ye ë ye ke thuɔ̱k duɔ̱ɔ̱r ke amatë Canada. The Royal Canadian Mounted Police ë raided cɔ̱ɔ̱tën ye në 2005 ku 2009. Ye ë dhïl dhɔl dhun ku cultivation, possession, ku trafficking. Ke dhun dhïl dhɔl thënë thuëth, Simpson ë wïn duëëny Canada ku piny Europe, tinë ye dhuk në Croatia ku piny Netherlands, tinë ye ke amatë aţuɔ̯yëdun tënë thuɔ̱p ke thär.

Me 2012, ye ë puöc Phoenix Tears: The Rick Simpson Story, thuɔ̱kë amatë ye, akɔ̱k tha̱r tha̱r tha̱r ye, ku ye guëïn aţuɔ̯yëdun ye. Ye ë thuɔ̱kë phoenixtears.ca në piny ye gɔɔl ke thuɔ̱kë ku amatë aţuɔ̯yëdun.

Cɔ̱ɔ̱tnë amatë ye tënën, Simpson ë thuɔ̱k ke amatë ye ku bë puɛ̱ɛ̱r: tha̱r tha̱r cannabis—aţuɔ̱p ke high-THC tha̱r tha̱r tha̱r tinë akɔ̱k ye—cä bë cure cancer ku akɔ̱k thïïc thɔkïk thiëëë. Ye ke thuɔ̱k ke pharmaceutical companies, government agencies, ku medical institutions ë thëëny amatë tënë kë puɛ̱ɛ̱r dhun thuɔ̱k ke akɔ̱ku. Ye ë ye amatë ye në dhäk ku akɔ̱k duɔ̱ɔ̱r kë ye.

Thɔkë ku guëïn tinë kɔ̱c ku South Sudan: Guëïn aţuɔ̯yëdun aţuɔ̱p ku conspiracy ë cuɔ̱n ke dhïl thuɔ̱k tinë amatë cannabis tënë, aţuɔ̱p ke tinë akɔ̱c ë dhïl dhɔl bë puɛ̱ɛ̱r. Me South Sudan, tinë thuɔ̱k ke institutional trust ë puɛ̱ɛ̱r dhun piny ke thär ke thuɔ̱p, cienë ye guëïn akɔ̱c. Kua ye, dhïl ke thuɔ̱k aţuɔ̱p puëth ye bë dhɔ̱k ke dhïl ke amatë aţuɔ̯yëdun.

Protocol RSO Tɔkɛ: Thuɔ̱k 60-Gram 90-Dhäk

Simpson ë ke thuɔ̱k ku amatë thuɔ̱k aţuɔ̱p ye në 60 gram (ɛmɛntɔ̱k 60 mL) tha̱r tha̱r tha̱r cannabis thunë abïk 90 dhäk. Ye ë thuɔ̱k ye tënë në amatë thuɔ̱k cancer, kua ye ke thuɔ̱k ye për akɔ̱k thïïc thɔkïk. Wëc ku kec töc amatë ye:

Yïnnë: Kɔ̱c 60 gram tha̱r tha̱r tha̱r THC ku dhäk abïk 90 dhäk. Simpson ë ye ye tënë në tha̱ri aţuɔ̱p ke cancer thiëëë.

Thuɔ̱k thuɔ̱k:

• Dhäk 1: Bëk ku amatë ku dhäkën në bëk dhïl thuak në thɔk—ɛmɛntɔ̱k 10-15 milligram tha̱r tha̱r—tinë kɔ̱c 3 dhäk dhäk. Amatë dhäk dhäk: ɛmɛntɔ̱k 30-45 milligram.
• Dhäk 2-5: Kɔ̱ɔ̱ri amatë në dhäk ë dhäk abïk 4 dhäk kë bë bäk dhun THC kɔ̱ɔ̱ri ku bë puɔ̱ynyic akɔ̱k psychoactive. Me amatë dhäk 5, kuɔ̱ɔ̱r në 1 gram (1,000 milligram) tha̱r tha̱r dhäk dhäk, kɔ̱ɔ̱r në 3 amatë abïk dhï̱t.
• Dhäk 5-12: Kɔ̱ɔ̱ri 1 gram dhäk dhäk, kɔ̱ɔ̱r në 3 amatë abïk dhï̱t në ɛmɛntɔ̱k 333 milligram amatë, kɔ̱ɔ̱ri kë tha̱r tha̱r 60 gram ë cɔ̱ɔ̱tnë.

Akɔ̱k thuɔ̱k:

• Kuɔ̱ɔ̱r—oral: Dhïk amatë tha̱r tha̱r në cɔ̱ɔ̱t (sublingual) ku yekë. Simpson ë ye oral ingestion ë puɛ̱ɛ̱r dhun në absorption thiëëë ku thuɔ̱k kuɔ̱ɔ̱r ke amatë tinë cancer tënë cɔ̱ɔ̱t.
• Yïnnë—topical: Ku skin cancer ku akɔ̱k thïïc thiëëë, kɔ̱ɔ̱k tha̱r tha̱r në piny, ɣänë ke thɛ̈ɛ̈k, ku yekë acïï dhäk 3-4 dhäk. Simpson ë kɔ̱ɔ̱k topical application ku oral dosing ku skin cancer.
• Ecä kë yeë—primary inhalation: Simpson ecä kë thuɔ̱k ye ke thuɔ̱k tha̱r tha̱r tha̱r thunë thuɔ̱k kuɔ̱ɔ̱r. Ye ecä kë thuɔ̱k thuɔ̱k ke dhïl dhɔl (pain, nausea) kua ye ke thuɔ̱k ke oral route ë puɛ̱ɛ̱r dhun në kuɔ̱ɔ̱r thiëëë.

Tolerance ku akɔ̱k psychoactive: Simpson ë thuɔ̱k ke patients develop tolerance dhun THC’s psychoactive akɔ̱k më 3-4 dhäk. Ye ye euphoria, sedation, ku disorientation ë puɛ̱ɛ̱r ke dhäk ku ye ke bë puɛ̱ɛ̱r dhun. Ye ë kɔ̱ɔ̱k patients ecä kë dhäk dhïl dhɔl ke bëk dhäk thunë me bɛk akɔ̱k dhun dhï̱nhël dhun, ku yekë yök kekë acë bɛk bëk kö ku bɛk operate machinery tinë titration. Ye ë yök ke ye kɔ̱ɔ̱k family members ke dhïl ke akɔ̱k tënë.

Post-protocol maintenance: Me amatë 60-gram course, Simpson ë ke thuɔ̱k ku maintenance dose 1-2 gram tha̱r tha̱r dhäk tëëë, tinë kɔ̱ɔ̱ri. Ye ë ye maintenance importante dhun tinë dhun ku bë puɔ̱ynyic cancer.

Dietary ku lifestyle: Simpson ë ke thuɔ̱k ku dietary changes tinë oil protocol, aţuɔ̱p ke kɔ̱ɔ̱ri sugar, acë bëk processed foods, ku bëk nutrition. Cienë ye ë ya tï̱të ku thuɔ̱k ye tënë.

Thɔkë ku guëïn tinë kɔ̱c ku South Sudan evaluating protocol: Cienë protocol ye thunë dhïl thuɔ̱k aţuɔ̱p ye aţëtë ye ku amatë ɣua̱th aţuɔ̱p ye, ecä thuɔ̱kë aţuɔ̯yëdun. Ke yök tëk:

• Acënë validation thuɔ̱k trial kek. Acënë published randomized controlled trials, cohort studies, ku documented case series evaluate cienë protocol 60-gram/90-dhäk yïnë cancer type ke condition.
• Ye thɔk crude, unstandardized material ku ecä standardized potency. Actual THC content per gram traditional RSO cïk piny kë thuɔ̱p.
• THC exposure dhïl dhɔl: Me peak dosing, patients cɔ̱ɔ̱tnë ɛmɛntɔ̱k 1 gram high-THC oil dhäk dhäk. Me acë 60-90% THC content, cienë ee 600-900 milligram delta-9 THC dhäk dhäk—adose dhïl dhɔl thuɔ̱p thunë acë thuɔ̱kë në controlled clinical settings. Ku context, FDA-approved synthetic THC drug dronabinol ee typically dosed 2.5-20 milligram dhäk dhäk.
• Risks dhïl dhɔl me cienë doses: Kɔ̱c 600-900 milligram THC dhäk dhäk cɔ̱ɔ̱tnë akɔ̱k dhïl dhɔl aţuɔ̱p ke severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, ku cannabis use disorder. Cienë akɔ̱k ee ke documented në GENERAL KNOWLEDGE section [1][13][14][15].
• Oncology context: Patients ku active cancer ee medically complex. Using unregulated, unstandardized cannabis oil në primary cancer treatment—potentially në place tëë proven therapies—introduces harm extending beyond oil itself.

Traditional RSO Ye tënë tëɛ̱në

Traditional RSO cuɔ̱n ke tha̱r tha̱r tha̱r cannabis aţuɔ̱p ye thunë Simpson ë cɔ̱ɔ̱tnë ku ye ke thuɔ̱k, ecä lab specifications ku regulatory standards.

Source material: Simpson ë cɔ̱ɔ̱tnë high-THC, indica-dominant cannabis strains. Ye ë thuɔ̱kë heavy, sedating indica genetics ku generally ke thuɔ̱kë ke sativa ke cancer treatment. Ye ë cɔ̱ɔ̱tnë cannabis ye ke thänë ku ye cɔ̱ɔ̱tnë në trusted growers. Acënë strain standardization—starting material cïk piny në availability ku growing season. Me South Sudan, tinë agricultural conditions cïk piny thuɔ̱p thunë Nova Scotia, cienë variability ë kuɔ̱ɔ̱ri në pronounced.

Extraction solvent: Simpson ë cɔ̱ɔ̱tnë naphtha—petroleum-based solvent commercially available në lighter fluid. Ye kuɔ̱ɔ̱ri ë 99% isopropyl alcohol në alternative. Ye ë warned ke butane ku acetone. Naphtha ku isopropyl alcohol kek food-grade, creating safety concerns dhïl dhɔl. Me South Sudan’s climate, solvent evaporation ku safety handling ë puɔ̱ynyic additional challenges.

Extraction process:

1. Dry ku semi-dry cannabis placed in container (typically bucket)
2. Covered ku solvent ku agitated ku dhäkë në minutes kë dissolve cannabinoids
3. Poured through filter (cheesecloth) into collection vessel
4. Repeated ku fresh solvent në same plant material
5. Combined solvent washes placed in rice cooker
6. Solvent evaporated në relatively low heat—sufficient kë decarboxylate THCa into THC ku destroy most volatile terpenes
7. Thick, dark oil remained at bottom
8. Final oil transferred into oral syringes

Appearance ku physical characteristics: Traditional RSO ee nearly black, thick, viscous, tar-like oil ku strong cannabis odor ku possible solvent-residual smell. Consistency ee sticky ku difficult kë handle në room temperature ku becomes more fluid when warmed slightly.

Cannabinoid profile:

• Primarily decarboxylated delta-9 THC—heat converted essentially all THCa
• Naturally occurring minor cannabinoids (CBD, CBN, CBC, CBG) present në natural ratios, but not controlled, measured, ku targeted
• No ratio control—profile entirely determined by source plant genetics ku growing conditions
• Estimated THC content: 60-90% total THC by weight, never lab-verified

Terpene content: Minimal kɔ̱ɔ̱ri. Solvent extraction dissolved terpenes, ku high-heat evaporation volatilized them në temperatures below cannabinoid degradation thresholds. Traditional RSO ee effectively stripped of terpene content.

Standardization ku testing: None. Every batch differed based on plant material, growing conditions, solvent purity, extraction technique, evaporation temperature/duration, ku maker’s process. No Certificate of Analysis, cannabinoid quantification, ku contaminant screening existed. Simpson operated before cannabis legalization ku standardized lab-testing infrastructure.

Residual solvent risk: Cienë ee one of most significant safety concerns. Naphtha ee complex petroleum hydrocarbon mixture that may contain benzene, toluene, xylene, ku other toxic/carcinogenic compounds. Incomplete solvent purging—very difficult kë verify without analytical chemistry equipment—leaves potentially harmful residues. Modern extraction uses food-grade ethanol ku supercritical CO₂ specifically kë address cienë problem.

Simpson’s Claims vs. The Evidence Record

Rick Simpson ë cɔ̱ɔ̱tnë therapeutic claims dhïl dhɔl: RSO cä cure cancer (aţuɔ̱p ke terminal cases) ku ee effective ke diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, multiple sclerosis, ku more. Ye ee adamant, consistent, ku public about cienë claims throughout ye ke amatë aţuɔ̯yëdun.

What Simpson ecä: Ye ecä scientist, physician, pharmacologist, ku researcher. Ye acä formal training në medicine, oncology, pharmacology, ku clinical research methodology. Ye never designed, conducted, funded, ku published clinical trial. Ye never submitted results kɛ̈ peer review. Ye evidence base consisted of personal experience, self-reported patient outcomes, ku informally gathered testimonials—ku no controls, independent verification, imaging confirmation, long-term follow-up, ku blinding.

What preclinical literature shows: Cannabinoid-cancer literature duɔ̱k thiëëë ku ee scientifically interesting:

• In vitro studies demonstrate THC ku CBD cä induce apoptosis, inhibit proliferation, ku reduce angiogenesis in certain cancer cell lines
• Animal model studies show some tumor-growth inhibition in mice ku rats
• Cienë findings generate legitimate scientific interest ku ongoing research

What preclinical literature ecä show:

• Cienë findings have not translated into proven human cancer cures. Gap between in vitro/animal results ku human clinical outcomes ee vast ku well-documented across oncology research
• No human clinical trial has demonstrated RSO ku any cannabis oil preparation cures cancer
• Several small human trials of cannabinoids in cancer contexts (particularly glioblastoma) have been exploratory, small, ku have not produced results supporting cancer-cure claims

Institutional positions:

• U.S. National Cancer Institute (NCI) acknowledges cannabinoids have been studied for potential anticancer effects in lab ku animal models but does not endorse cannabis ku cannabis oil në cancer treatment
• FDA has not approved any cannabis plant product for cancer treatment. Only FDA-approved cannabinoid-related products ee for other specific indications: Epidiolex (CBD) for certain seizure disorders ku dronabinol/nabilone (synthetic THC analogues) for chemotherapy-related nausea ku AIDS-related wasting
• Health Canada has never approved RSO ku cannabis oil në cancer cure
• NCCIH explicitly states strongest cannabinoid evidence ee for rare epilepsies, chemotherapy-related nausea/vomiting, ku appetite-related indications in HIV/AIDS—not cancer cure

What Simpson got right: Ye drew attention kɛ̈ cannabinoids në serious biomedical research area when most of world ignored ku suppressed that conversation. Ye ke amatë aţuɔ̯yëdun—however scientifically imprecise—helped create political, cultural, ku social conditions for legal cannabis industry ku cannabinoid research infrastructure that exists today. Ye was among first kɛ̈ bring concentrated cannabis oil kɛ̈ widespread public awareness, ku term RSO remains most recognized name for full-spectrum cannabis extract in consumer vocabulary. Cienë contributions ee real ku historically significant.

What ye overstated: leap from preclinical signals kɛ̈ cancer cure ecä not supported by human evidence when Simpson made it, ku it ee not supported now. Encouraging patients—particularly cancer patients—kɛ̈ rely on RSO në primary treatment in place tëë proven oncologic therapies (surgery, radiation, chemotherapy, immunotherapy) carries genuine harm potential. Delayed ku foregone treatment for treatable cancers ee documented concern in alternative-medicine literature. Simpson’s absolute certainty about curative claims exceeded what evidence could support ku still exceeds it today.

The Legacy ku Evolution of Modern RSO

Term RSO ee now used broadly ku loosely across legal cannabis industry. Many products labeled RSO bear little resemblance kɛ̈ what Simpson originally made. In dispensaries today, RSO cɔ̱n refer kɛ̈ almost any full-spectrum cannabis extract sold in syringe format, regardless of extraction method, cannabinoid profile, terpene content, ku intended use. Term has become generic.

Simpson ye has been critical of commercial products using RSO name while departing significantly from ye original method ku philosophy. Ye has publicly stated many products sold as RSO do not meet ye standards ku that commercialization contradicts ye original intent. Simpson’s model was explicitly anti-commercial—ye gave oil away free ku urged others kɛ̈ make their own rather than buy from companies.

Cienë philosophical tension ee worth acknowledging. Simpson believed in do-it-yourself, free-access model where anyone could grow cannabis, extract oil, ku treat themselves without corporate ku governmental intermediaries. Modern cannabis industry has done something very different: commercialized, standardized, ku regulated what Simpson distributed for free. Whether that evolution represents improvement (quality control, lab testing, dosing precision) ku betrayal (profit extraction, regulatory gatekeeping) depends on perspective, ku cannabis community remains divided.

What ee not disputed ee that modern RSO has evolved substantially from its origins, ku those changes ee directly relevant kɛ̈ formulas in this document.

Traditional RSO vs. Modern Formulated RSO

Dimension	Traditional RSO	OilWell Formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha ku isopropyl alcohol	Modern food-grade ethanol ku CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% ku defined seven-terpene profile
Standardization	None—every batch different	Lab-tested ku specific mg/mL targets (553 mg/mL)
Lab testing	Not available ku performed	Full panel testing (potency, terpenes, pesticides, heavy metals, residual solvents, microbial)
Residual solvents	Significant risk ku naphtha	Controlled ku tested—solvent-free production
Dosing precision	Approximate, syringe-based	Measured per mL ku known cannabinoid content
Product formats	Single thick oil only	Sublingual oil ku vape cartridge ku format-specific formulas
THCa preservation	No—fully decarboxylated by heat	Yes—THCa included as separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted ku peer-reviewed citations
Accessibility	Illegal kɛ̈ produce/ship	Farm Bill compliant, ships kɛ̈ South Sudan ku proper documentation

Why OilWell’s Formulas Diverge from Traditional RSO

Our formulations ee not traditional RSO. They ee informed by RSO tradition but depart deliberately in evidence-motivated ways that solve problems limiting Simpson’s original vision:

Multi-cannabinoid approach. Traditional RSO relied on whatever single strain maker grew ku sourced. Our formulas intentionally include seven cannabinoids—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, ku CBC—because entourage-effect literature suggests potential benefit from cannabinoid diversity, even though robust clinical proof of whole-formula synergy remains limited [20][29]. In South Sudan, where patients often face multiple concurrent health challenges, cienë multi-pathway approach may be particularly relevant.

Terpene preservation ku addition. Traditional RSO had essentially no terpene content due kɛ̈ solvent ku heat destruction. We include live terpenes at 5% ku specific seven-terpene profile—limonene, myrcene, caryophyllene, pinene, linalool, humulene, ku terpinolene—because terpene bioactivity ee plausible ku supported at preclinical level, even if human clinical confirmation for cannabis-specific terpene effects ee still developing [20][21][23][24][25][26][27][28][29]. aromatic profile also makes product more palatable ku South Sudanese users accustomed kɛ̈ herbal medicines.

THCa as separate ingredient. Traditional RSO fully decarboxylated everything, converting all THCa into delta-9 THC. Our sublingual formula includes THCa at 1,500 mg as distinct ingredient, preserving acidic precursor because THCa literature suggests potentially relevant non-psychoactive bioactivity that is lost when THCa converts kɛ̈ THC [12]. Cienë ee crucial for South Sudanese patients who need daytime relief without impairment.

Reduced delta-9 THC dominance. Traditional RSO was 60-90% delta-9 THC. Our sublingual formula uses delta-9 THC at only 90 mg while incorporating delta-8 THC at 6,000 mg ku distributing remaining cannabinoid content across CBD (4,500 mg), CBG (3,000 mg), CBN (750 mg), ku CBC (750 mg). Cienë reflects broader cannabinoid research landscape rather than single-compound dominance.

Product format innovation. Simpson envisioned only one format: oral oil from syringe. We offer both 30 mL sublingual oil ku 1-gram vape cartridge, each ku format-specific formulation acknowledging that different delivery routes have different pharmacokinetic profiles [14]. For South Sudan’s diverse geography—from urban Juba kɛ̈ remote rural areas—having multiple format options matters.

Solvent Safety ku Extraction Evolution

Traditional RSO production used naphtha ku isopropyl alcohol—neither food-grade. Naphtha ee complex petroleum hydrocarbon mixture that may contain benzene, toluene, xylene, ku other toxic/carcinogenic compounds. Incomplete solvent purging—very difficult kɛ̈ verify without analytical chemistry equipment—leaves potentially harmful residues in finished oil.

Modern cannabis extraction overwhelmingly uses food-grade ethanol ku supercritical carbon dioxide (CO₂). Ni methods allow much more complete solvent removal, ku finished products can be tested for residual solvents using validated analytical methods like headspace gas chromatography. Cienë ee one of most straightforward improvements modern regulated cannabis industry has made over traditional RSO production.

Cienë evolution connects directly kɛ̈ product-quality discussion in our GENERAL KNOWLEDGE section, which emphasizes that product quality matters as much as molecule identity ku that labeling inaccuracies, contamination, synthesis byproducts, ku dose variability all materially affect interpretation in real-world products [1][10][11][14].

The Decarboxylation Question

Traditional RSO was fully decarboxylated. Heat involved in evaporating solvent from rice cooker—typically sustained at ku near solvent’s boiling point (60-80°C for naphtha, 82°C for isopropyl alcohol)—was sufficient kɛ̈ convert essentially all THCa in extract into delta-9 THC. Ko result, acidic cannabinoids that exist abundantly in raw cannabis—THCa, CBDa, CBGa, ku others—were lost as distinct compounds.

Our sublingual formula deliberately preserves THCa at 1,500 mg as separate ingredient. Cienë intentional formulation choice ee informed by THCa evidence profile, which notes that THCa itself does not produce psychoactive effects associated with THC, but its interpretation depends on route, temperature, processing, ku storage—because THCa can convert kɛ̈ THC under heating ku over time [12].

For South Sudanese customers, cienë means one product serves multiple needs. Raw use provides non-psychoactive anti-inflammatory benefits for daytime functionality. Home decarboxylation (heating at 260°F/125°C for 45-60 minutes) converts THCa kɛ̈ delta-9 THC, creating psychoactive potency comparable kɛ̈ traditional illegal RSO—entirely at customer’s discretion after legal purchase.

Terpene Loss in Traditional RSO

Terpenes ee volatile aromatic compounds ku relatively low boiling points. Most cannabis terpenes begin volatilizing at 21-157°C, ku many abundant terpenes (myrcene, limonene, pinene) boil below 180°C. Traditional RSO production destroyed terpenes in two ways: dissolving them into solvent wash along ku cannabinoids, ku evaporating them during high-heat solvent removal.

Ko meant traditional RSO was essentially cannabinoid-only product, despite being derived from terpene-rich plant. Whatever aromatic, flavoring, ku potentially bioactive terpene compounds source cannabis contained were lost in production.

Our formulas specify live terpenes at 5% ku defined seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, ku terpinolene. Each terpene has its own evidence profile in our GENERAL KNOWLEDGE section. Entourage-effect literature [20][29] provides theoretical framework for why preserving ku including terpenes alongside cannabinoids may matter pharmacologically, even though robust human clinical proof of cannabis-specific entourage effects remains limited.

Evidence Standards Then ku Now

Rick Simpson operated in pre-legalization, pre-lab-testing era. When ye began making ku distributing oil in early 2000s, cannabis was illegal in Canada ku most of world. There was no regulatory framework, standardized testing infrastructure, legal pathway for clinical research, ku peer-reviewed journals dedicated kɛ̈ cannabis therapeutics. Cannabis underground was only access point, ku personal experience was primary evidence currency.

Simpson’s methods reflected those constraints. Ye evidence was anecdotal. Ye production was unstandardized. Ye claims were untested in any formal sense. Cienë ee not necessarily moral failing—it ee description of environment in which ye operated.

Cienë document takes fundamentally different approach. Our GENERAL KNOWLEDGE section applies formal evidence hierarchy: human clinical evidence first, then systematic reviews ku meta-analyses, then institutional summaries, then preclinical ku mechanistic literature [1]-[29]. Every compound-level claim ee tied kɛ̈ specific peer-reviewed sources ku evidence strength clearly labeled.

Our intent ee kɛ̈ honor historical origin of RSO while committing kɛ̈ standards of modern cannabinoid science. Where Simpson relied on personal testimony, we rely on published literature ku institutional sources. Where ye had no access kɛ̈ peer-reviewed literature, we have that access ku use it kɛ̈ distinguish between what ee well-supported, what ee emerging, ku what ee overstated.

Cienë matters profoundly for South Sudan, where misinformation about medical treatments has cost lives. Our commitment kɛ̈ evidence-based education ee not academic—it ee moral imperative.

Simpson’s Protocol vs. Modern Dosing Considerations

Simpson’s 60-gram/90-day protocol was designed around crude, single-strain, THC-dominant extract ku no standardized potency. Direct comparison between ye dosing recommendations ku dosing ku modern, standardized, multi-cannabinoid formulation ee not straightforward—products ee fundamentally different.

Key differences illustrating why:

• Cannabinoid concentration: Our sublingual formula delivers 553 mg of total active cannabinoids per mL across seven defined compounds. Traditional RSO potency was unknown ku variable.
• Cannabinoid ratios: Simpson’s oil was approximately 60-90% delta-9 THC. Our formula distributes 16,590 mg of total cannabinoids across CBD (4,500 mg), CBG (3,000 mg), delta-8 THC (6,000 mg), THCa (1,500 mg), delta-9 THC (90 mg), CBN (750 mg), ku CBC (750 mg).
• Terpene presence: Simpson’s oil had no terpenes. Our formula includes live terpenes at 5%.
• Delta-9 THC exposure: Simpson’s protocol at peak delivered 600-900 mg of delta-9 THC per day. Our sublingual formula contains only 90 mg of delta-9 THC in entire 30 mL bottle (3 mg per mL), making per-dose delta-9 THC exposure dramatically lower.

For South Sudanese customers, cienë means our products require different dosing approaches than Simpson’s protocol. Our dosing guidance ee developed independently of Simpson’s protocol, informed by per-compound evidence in our GENERAL KNOWLEDGE section ku responsible titration principles accounting for safety profiles of each individual cannabinoid.

The OilWell Story: Ku Houston to̱k South Sudan

Origin ye: Dog Wïn E Bentley

OilWell Cannabis ee founded by Colin Valencia në Houston, Texas. Colin ë bïkäɔ̱ɔ̱kɛ McAllen, Texas—right across river from Reynosa, Tamaulipas, Mexico. McAllen-Reynosa area, known as Borderplex, ee one of most economically challenged ku dangerous regions along U.S.-Mexico border. McAllen ee city of contrasts—vibrant culture ku thriving retail sector, yet deeply affected by poverty ku limited opportunities. Reynosa ee industrial hub plagued by violence ku cartel activity.

Colin’s childhood was marked by exposure kɛ̈ border complexities ku dangers. Early on, ye learned kɛ̈ hustle, taking on risky work transporting items across border. Ye faced every form of violence imaginable, both in streets ku across border. By sixteen, ye had kɛ̈ leave home for good. Many South Sudanese readers will recognize cienë experience—forced displacement, economic survival through informal economies, ku facing violence from multiple directions.

Despite dangers, Colin did not fall into darkest paths like selling harder substances. Instead, ye focused on cannabis, seeing it as safer ku more beneficial alternative. Ye grew up in traditional cannabis world long before legalization, learning plant intimately while operating in shadows. Over time, ye transitioned from early, risky ventures kɛ̈ creating legal, legitimate business in industry ye believes in.

Colin later became formally trained software engineer ku did custom development work for Baylor College of Medicine, one of most prestigious medical institutions in Texas Medical Center. That combination—deep cannabis plant knowledge plus medical-grade technical precision—defines OilWell’s approach.

Our origin story begins with dog named Bentley. Bentley was more than pet—ye was family, companion who stood by Colin through toughest times. When Bentley fell seriously ill, veterinarians delivered verdict no pet owner wants: euthanasia was only humane option. Bentley was paralyzed in his back legs. They said pain medications would destroy his internal organs, causing more suffering. Choice was painful prolonged decline ku immediate mercy killing.

But giving up on Bentley was not option. Colin had already faced too much loss ku seen too much suffering. Bentley was fighter, just like him. In desperate search for alternatives, ye stumbled upon CBD through question that changed everything.

Kind-hearted rescue worker named Jessica asked Colin: “You’ve moved how many tons of weed ku you’ve never heard of CBD?”

Colin had cannabis experience—but it was recreational. Ye had never explored therapeutic applications. Jessica’s question exposed blind spot that became mission.

Determined kɛ̈ save Bentley, Colin learned kɛ̈ create CBD golden paste—specialized cannabinoid formula for pets. It was not cure, but it was lifeline ku hope. Ku that hope delivered something veterinary medicine said was impossible: Bentley got up. Ye walked over kɛ̈ Colin ku brought him his ball kɛ̈ play. From paralyzed facing euthanasia kɛ̈ fetching his ball—this was not placebo effect. Dogs do not respond kɛ̈ placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced. Neurodegeneration led him kɛ̈ understand CBG’s neuroprotective properties ku THCa’s PPARγ agonism for brain cell protection. Dementia led him kɛ̈ CBC’s role in neurogenesis. Glaucoma led him kɛ̈ THC’s CB1 agonism for intraocular pressure reduction. Crippling arthritis led him kɛ̈ develop multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, ku beta-caryophyllene working through different receptor systems simultaneously.

Why cienë matters for South Sudan: Multi-cannabinoid approach that defines our RSO formula was not born in lab—it was born from necessity, from keeping loved one alive for decade. Single cannabinoids were not enough. Bentley’s evolving conditions required synergy. Pharmaceutical precision mattered—Bentley’s life depended on formula accuracy, not guesswork. This same principle applies kɛ̈ complex health challenges faced by people across South Sudan.

Our Personal Connection kɛ̈ Suffering

Colin also knows pharmaceutical dependence personally. Ye struggled with PTSD ku benzodiazepine addiction. When ye decided kɛ̈ break free from Xanax, ye did it cold turkey—feat notoriously difficult ku dangerous—using cannabinoid knowledge developed keeping Bentley alive.

Peace Gummies formula that became OilWell product was created during midnight experiments while fighting through benzo withdrawal. Kɛ̈ ensure quick relief, we also offer Peace Gummies formula in vape form, which Colin personally uses kɛ̈ manage his insomnia ku severe PTSD. This ee not theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, discovery that cannabinoids work when pills do not.

Over time, therapeutic benefits Colin first discovered through Bentley became our core work. We’ve developed formulas that doctors use for conditions like Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, ku insomnia. Our focus has always been making cannabis accessible ku effective for everyone, including vegans, diabetics, ku those with specific health needs.

ABC13 KTRK Houston—Houston’s number-one news source—featured Colin ku OilWell Cannabis in seven comprehensive news segments spanning 2019-2023, covering Texas marijuana law, Delta-8 legal analysis, COVID-19 community health leadership, criminal justice reform, ku cannabis business pioneering. Colin was repeatedly selected as primary industry expert for cannabis policy ku product coverage in America’s fourth-largest city.

Colin’s quote from our first ABC13 feature in September 2019 captures our philosophy: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

Our Current Operations ku Commitment

Today, OilWell Cannabis operates from Montrose, Houston, Texas (810 Richmond Avenue, Houston, TX 77006). We’ve been operating since 2019, generate approximately one million dollars in annual revenue, maintain near-5.0 Google rating, ku are Texas DSHS licensed. Our products are not mass-produced—they ee carefully crafted with personal touch, from artwork on packaging kɛ̈ formulations inside. All artwork, formulations, ku packaging are created in-house in Houston, using only our own recipes ku ideas.

Colin brings Houston grit, McAllen roots, ku builder’s mindset kɛ̈ our company, but our posture stays simple: make products with intent, answer directly, ku never pretend cannabis ee right for everyone.

The OilWell RSO Philosophy for South Sudan

Our RSO ee not traditional Rick Simpson Oil. It ee formulated, multi-cannabinoid product informed by RSO tradition but departing from it in deliberate, evidence-motivated ways designed kɛ̈ solve problems that limited Rick Simpson’s original vision.

Four Core Principles Defining Our Approach

1. Accessibility over gatekeeping. No medical card ee required. Anyone age twenty-one ku older can purchase. We ship nationwide across United States ku internationally kɛ̈ South Sudan ku other countries where customers verify local legality. Rick Simpson believed medicine should be accessible kɛ̈ everyone; we built product ku distribution model that makes that accessible legally, even kɛ̈ customers in Juba, Wau, Malakal, ku rural South Sudanese communities.

2. Patient-controlled potency. THCa ee sold in its acidic, non-psychoactive form. You decide whether kɛ̈ use it raw for non-psychoactive benefits ku kɛ̈ decarboxylate it into delta-9 THC for full psychoactive potency. Rick Simpson believed patients should control their own medicine; we engineered product that puts that control in your hands through chemistry rather than rhetoric. For South Sudanese patients who must work, farm, care for families, ku commute during day, cienë non-psychoactive option ee revolutionary.

3. Open-source formulas. We publish our complete formulas publicly—every cannabinoid, every milligram amount, every percentage—so that anyone who cannot afford our products can source ingredients ku make their own version. Rick Simpson gave his oil away free ku taught people how kɛ̈ make it; ye never patented his method. We adapted that ethos for modern cannabinoid marketplace: we sell professionally manufactured, lab-tested, standardized product for those who want it, ku we publish complete recipe for those who want kɛ̈ make it themselves.

Cienë ee particularly relevant for South Sudan, where economic constraints are significant. If our $129.99 sublingual oil ku $49.99 vape cartridge ee beyond your means, you can see exactly what formula contains ku work with local resources kɛ̈ create your own version.

4. Evidence-informed, not evidence-overstating. Our GENERAL KNOWLEDGE section represents our commitment kɛ̈ honest education about what science actually says. Rick Simpson operated without access kɛ̈ peer-reviewed literature ku clinical trial data; we have that access ku use it kɛ̈ distinguish what ee well-supported, what ee emerging, ku what ee overstated.

For South Sudanese readers navigating complex health landscape, cienë commitment kɛ̈ truth-telling ee essential. We will not promise cures we cannot deliver. We will tell you exactly what research shows for each cannabinoid ku terpene, so you can make informed decisions for yourself ku your family.

Farm Bill Compliance ku International Shipping kɛ̈ South Sudan

2018 Farm Bill (Agricultural Improvement Act) legalized hemp ku hemp-derived products containing less than 0.3% delta-9 THC by dry weight at federal level in United States. Cienë legal framework ee foundation of our RSO product design.

Our RSO Sublingual Oil contains only 90 milligram delta-9 THC in entire 30 mL bottle—3 milligram per milliliter—well under 0.3% threshold. All cannabinoids in formula are hemp-derived. Product ee legal under U.S. federal law ku in most states.

THCa—tetrahydrocannabinolic acid—ee acidic, non-psychoactive precursor kɛ̈ delta-9 THC. It ee not itself delta-9 THC. Cienë distinction ee legally significant: THCa ee Farm Bill compliant at point of sale because it has not been converted kɛ̈ delta-9 THC.

Practical significance for South Sudan: You can legally purchase, possess, ku transport our products because they meet international hemp product standards. We ship internationally with full documentation, Certificates of Analysis (COAs), ku receipts for customs purposes. Product ee temperature-stable ku packaged discreetly.

THCa conversion chemistry: When you heat our oil at 260°F (125°C) for 45-60 minutes in oven-safe glass container, 1,500 milligrams THCa converts kɛ̈ approximately 1,315 milligrams delta-9 THC. Combined with existing 90 milligrams delta-9 THC, cienë yields approximately 1,405 milligrams total delta-9 THC. This gives product psychoactive potency comparable kɛ̈ traditional illegal RSO—entirely at your discretion after legal purchase.

Conversion ratio ee approximately 1 milligram THCa = 0.877 milligrams delta-9 THC after decarboxylation, reflecting loss of CO₂ molecule during reaction.

Important legal notice for South Sudan customers: THCa converts kɛ̈ delta-9 THC when heated. You are responsible for understanding ku complying with South Sudan laws regarding cannabinoid products. We ship with full documentation, COAs, ku receipts. International customers accept all customs ku legal responsibility. We strongly encourage you kɛ̈ verify current regulations in South Sudan before ordering.

We cannot provide legal advice specific kɛ̈ South Sudan’s regulatory framework, as cannabis laws vary by country ku can change. However, we can confirm our products meet U.S. Farm Bill standards for hemp-derived products, which aligns with international hemp trade regulations.

Open-Source Formulas: Our Commitment kɛ̈ Transparency

We publish our complete RSO formulas publicly—every cannabinoid, every milligram amount, every percentage—so anyone who cannot afford our products can source ingredients ku make their own version. Formulas are detailed later in this document, but principle ee simple: we sell professionally manufactured product ku publish recipe.

Cienë ee direct echo of Rick Simpson’s original ethos. Ye gave his oil away free ku taught people how kɛ̈ make it. Ye never patented his method. We adapted that ethos for modern cannabinoid marketplace.

As Colin said on ABC13 in 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

Open-source philosophy started with Bentley. On our About Us page, Colin published actual CBD golden paste recipe that saved Bentley’s life, so any pet owner facing similar crisis could make it themselves:

CBD Golden Paste Recipe for Pets—Original Open-Source Formula

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1-2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on size ku needs; consult veterinarian)

Instructions:

1. Mix turmeric ku water in saucepan over low heat, stirring continuously until thick paste forms (7-10 minutes). Add more water if too thick.
2. Add coconut oil ku black pepper. Stir until thoroughly mixed.
3. Cool ku store in refrigerator for up kɛ̈ two weeks.
4. Add small amount of CBD oil before giving kɛ̈ pet, adjusting dosage by weight ku health needs. Start low ku increase gradually.

Serving suggestion: Mix small amount with pet’s food once ku twice daily. Monitor for changes ku consult veterinarian with concerns. Always consult veterinarian before starting any new supplement regimen.

Cienë recipe—published free, years before our RSO formulas—demonstrates that open-source ee our foundational behavior, not marketing strategy. For South Sudanese pet owners facing veterinary care limitations, cienë recipe ee immediately useful.

Decarboxylation Choice: You Control Potency

Traditional RSO was always fully decarboxylated. Heat of solvent evaporation converted all THCa into delta-9 THC, leaving patients no choice about psychoactivity—oil was always psychoactive.

Our sublingual formula contains 1,500 milligrams THCa in its acidic, non-psychoactive form. Cienë creates three distinct usage options:

Option 1—Raw, no heat: All 1,500 milligram stays as THCa—completely non-psychoactive. THCa evidence profile describes potential anti-inflammatory activity via COX-2 inhibition ku neuroprotective potential via PPARγ agonism [12]. Cienë option ee compatible with work, driving, farming, ku daytime use with zero psychoactive impairment—critical for South Sudanese farmers, traders, ku professionals.

Option 2—Fully activated, home decarboxylation: Heating oil at 260°F (125°C) for 45-60 minutes in oven-safe glass container converts 1,500 milligram THCa kɛ̈ approximately 1,315 milligram delta-9 THC. Combined with existing 90 milligram delta-9 THC, cienë yields approximately 1,405 milligram total delta-9 THC. Combined with 6,000 milligram delta-8 THC, activated product achieves psychoactive potency comparable kɛ̈ traditional high-THC RSO—100% legally, because decarboxylation occurs at your discretion after purchase. You can also transfer controlled portion from original bottle into second oven-safe container, decarboxylating only what you intend kɛ̈ use while preserving remainder raw.

Option 3—Vape, auto-decarboxylation: Our RSO Vape Cartridge vaporizes at 400-450°F, instantly converting THCa kɛ̈ delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids. Cienë ee fastest-onset RSO delivery method available—1-2 minute onset versus 15-45 minutes for sublingual.

Cienë design puts potency decision entirely in your hands—aligning with Rick Simpson’s principle that patients should control their medicine, but implementing it through actual product chemistry rather than one-size-fits-all approach.

Solvent-Free Production ku Safety

Our RSO ee not traditional extraction product. It ee formulated blend of individual cannabinoid distillates ku isolates combined at specific ratios in controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents are present in finished product.

Cienë eliminates residual solvent risk that ee one of most significant safety concerns with traditional RSO production, as discussed in Rick Simpson section.

We use organic MCT oil (medium-chain triglycerides) as carrier base. MCT oil ee food-grade lipid carrier that facilitates cannabinoid absorption through sublingual tissue ku provides neutral taste profile—significant improvement over tar-like consistency ku solvent-residual odor of traditional RSO.

Third-party lab testing covers cannabinoid potency, terpene profile, ku safety panels including pesticides, heavy metals, residual solvents, ku microbial contaminants. Certificates of Analysis (COAs) are available on request ku accessible through our website.

For South Sudanese customers, cienë level of testing ee especially important. In regions where regulatory oversight may be limited, our commitment kɛ̈ third-party verification provides assurance that you are getting exactly what label claims—no contaminants, no surprises.

Our Broader Product Portfolio

Beyond RSO, we produce range of cannabinoid products, each developed from formulation knowledge Colin built over Bentley’s ten-year journey ku his own experience with PTSD ku benzo withdrawal.

Asshole Peach—$39.99 (Our most popular product): Carefully formulated kɛ̈ provide euphoric, long-lasting sensation. Particularly favored by veterans for relieving pain ku PTSD symptoms without being overly aggressive. For South Sudanese veterans ku conflict survivors dealing with trauma, cienë product offers non-pharmaceutical option.

Peace Gummies—$34.99 (Sleep & recovery): Developed directly from Colin’s own experience with PTSD ku benzodiazepine addiction. Peace Gummies helped him quit Xanax cold turkey. Formula ee also available in vape form for quick relief—Colin personally uses vape kɛ̈ manage his insomnia ku severe PTSD. For South Sudanese patients struggling with sleep disturbances common in post-conflict settings, cienë offers targeted solution.

SWEETEMintz Sugar-Free Vegan Peppermint Hard Candy—$39.99: Contains 28mg Delta-9 Nano THC, 100mg Nano CBD, 50mg CBG Isolate. Zero sugar, 100% vegan—designed for diabetic ku health-conscious consumers. For South Sudan’s growing diabetic population, cienë provides cannabis option that won’t impact blood sugar.

Custom creations: We design tailored products on request for specific cannabinoid ratios, delivery formats, ku health circumstances, including formulations for vegans, diabetics, ku those with specific dietary needs. If you have unique health requirements related kɛ̈ South Sudan’s specific disease burden ku dietary traditions, we can formulate specifically for your community.

Two Product Formats for Different South Sudan Needs

We offer RSO formula in two delivery formats, each designed for different use cases ku pharmacokinetic profiles.

RSO Sublingual Oil—$129.99

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg per mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper for precise dosing in 0.1 mL increments
• Onset: 15-45 minutes (sublingual absorption)
• Peak effects: 1-2 hours
• Duration: 4-6 hours
• Bioavailability: 13-19% (partially bypasses first-pass liver metabolism)
• Approximately 40-60 doses per bottle depending on serving size

RSO Vape Cartridge—$49.99

• 1-gram cartridge
• 900+ mg total cannabinoids
• Same six-cannabinoid ratio as sublingual formula
• Live terpenes at 5%+
• 510-thread universal battery compatibility (batteries widely available in South Sudan’s urban centers)
• Onset: 1-2 minutes (fastest cannabinoid delivery method)
• Peak effects: 10-15 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35% (variable by inhalation technique)
• Automatic THCa decarboxylation at vaping temperature (400-450°F)

When kɛ̈ Use Each Format kx South Sudan

Use case	Recommended format	Rationale
Fast relief (acute pain, nausea, panic attack, trauma trigger)	Vape	1-2 minute onset—critical for breakthrough symptoms
Sustained relief (chronic pain, sleep maintenance)	Sublingual	4-6 hour duration—ideal for overnight ku all-day management
Maximum bioavailability	Sublingual	13-19% absorption—more efficient use of cannabinoids
Portability ku discretion (markets, social gatherings)	Vape	Compact, no measuring required—discreet use
Precise dosing control (titration for sensitive patients)	Sublingual	Graduated dropper in 0.1 mL increments—start very low
Daytime non-psychoactive use (farming, work, driving)	Sublingual (raw, no heat)	THCa stays inactive, zero impairment—function normally
Nighttime psychoactive use (severe pain, sleep initiation)	Sublingual (decarbed) ku Vape	Activated THCa + delta-8 THC for strong evening effects

Competitive Comparison: Why South Sudanese Customers Choose OilWell

OilWell RSO vs. Traditional Illegal RSO (South Sudan Market)

Dimension	Traditional RSO (Black Market)	OilWell Formulated RSO
Legality in South Sudan	Uncertain, potentially illegal	Ships legally with documentation; customer must verify local laws
Cannabinoid profile	Unknown, variable, THC-dominant	Seven defined cannabinoids at precise ratios
Terpene content	Destroyed	Live terpenes at 5% ku defined profile
Standardization	None—every batch different	Lab-tested ku specific mg/mL targets (553 mg/mL)
Safety testing	None	Full panel (pesticides, heavy metals, residual solvents, microbial)
Residual solvents	High risk ku naphtha/isopropyl	Solvent-free production
Dosing precision	Approximate syringe-based	Measured per mL ku graduated dropper
Product formats	Single thick oil only	Sublingual oil + vape cartridge
THCa preservation	No—fully decarboxylated	Yes—1,500 mg separate ingredient
Evidence approach	Anecdotal only	Research-backed with peer-reviewed citations
Access for South Sudan	Difficult/illegal kɛ̈ import	International shipping with COAs ku documentation

OilWell RSO vs. Generic CBD Oils (South Sudan Market)

Feature	Generic CBD Oil (500-1000mg)	OilWell RSO
Total cannabinoids	500-1,000 mg	16,590 mg
CBD content	400-950 mg	4,500 mg
CBG content	0-50 mg	3,000 mg
CBN content	0-10 mg	750 mg
CBC content	0-50 mg	750 mg
Delta-8 THC	0 mg	6,000 mg
THCa (convertible)	Minimal	1,500 mg
Terpenes	Often none ku synthetic	Live terpenes at 5%
Psychoactive option	No	Yes—via THCa decarboxylation
Price point	$40-80	$129.99 (33 doses at max strength = $3.94/dose)

Math ee clear: Our sublingual oil provides 16.5x more total cannabinoids than typical CBD oils, with seven cannabinoids instead of one ku two. For South Sudanese customers managing severe conditions, cienë concentration difference ee not incremental—it ee transformative.

Condition-Specific Usage Context for South Sudan

Important disclaimer: Following usage contexts ee informed by cannabinoid research cited in our GENERAL KNOWLEDGE section ku by our formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, ku not substitute for professional medical care. These products have not been evaluated by Food ku Drug Administration ku are not intended kɛ̈ diagnose, treat, cure, ku prevent any disease. Always consult qualified healthcare provider before using cannabinoid products, especially if you have medical condition, ecä taking medications, ecä pregnant ku nursing, ku have health concerns. Do not operate vehicles ku machinery while under influence of psychoactive cannabinoids.

Chemotherapy-related nausea ku appetite support (for cancer patients in South Sudan accessing treatment in Juba ku traveling abroad):

• Pre-chemo: 0.5-1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2-3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0-2.0 mL sublingual before bed (delivers 25-50 mg CBN)
• Evidence context: delta-8 THC antiemetic evidence [9], delta-9 THC nausea/vomiting evidence [1][13], CBD anxiolytic buffering [3]

Chronic pain (fibromyalgia, arthritis, neuropathy, injury-related pain common in South Sudan):

• Daytime: 0.3-0.5 mL raw sublingual—provides anti-inflammatory cannabinoid exposure without psychoactive impairment (compatible with farming, trading, caregiving)
• Nighttime: 0.5-1.0 mL decarboxylated sublingual—combines pain relief ku CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset
• Evidence context: CBD pain evidence [4], delta-9 THC pain evidence [13], beta-caryophyllene CB2 agonism [24], THCa COX-2 inhibition [12]

Sleep support (for insomnia common in post-conflict populations):

• Before bed: 1.0-2.0 mL sublingual
• At 2.0 mL, this delivers 50 mg CBN—dosage level investigated in 2024 sleep literature
• At 1.0 mL, this delivers 25 mg CBN—above 20 mg threshold associated with reduced sleep disturbance
• Evidence context: CBN sleep evidence [16][17], cannabis ku sleep review literature

Anxiety ku stress (for PTSD, trauma survivors, daily stressors in challenging environments):

• Daytime functional relief: 0.3 mL raw sublingual—CBD ku CBG address anxiety pathways without psychoactive impairment
• Nighttime: 1.0 mL sublingual—full cannabinoid profile including CBN for sleep architecture
• Evidence context: CBD anxiety evidence [3], CBG pharmacology [7][8], limonene entourage-effect evidence [20]

Malaria recovery support (common in South Sudan):
While not specifically studied, anti-inflammatory properties of THCa [12], CBD [4], ku beta-caryophyllene [24] may support recovery from inflammatory episodes. Immunomodulatory potential of CBG [7] ee also being explored in preclinical research. This remains exploratory ku should complement, not replace, antimalarial treatment.

General titration principle for South Sudanese users: Start low, go slow. Begin with 0.25-0.5 mL sublingual ku assess effects over 2-3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, ku other factors. Given limited access kɛ̈ specialized medical care in many parts of South Sudan, conservative titration ee especially important.

Delivery ku Accessibility kɛ̈ South Sudan

We ee proud kɛ̈ offer international shipping kɛ̈ South Sudan, making our RSO formulas accessible kɛ̈ customers in Juba, Wau, Malakal, ku throughout country.

International shipping kɛ̈ South Sudan:

• All packages include full documentation, Certificates of Analysis (COAs), ku receipts for customs purposes
• Discreet packaging with no cannabis branding visible
• Temperature-stable packaging for South Sudan’s hot climate
• Tracking provided for all orders
• Signature-required option available
• Customer ee responsible for verifying legality in South Sudan ku accepts all customs ku legal risk
• Contact: (832) 416-2816 ku [email protected] for shipping quotes ku customs guidance

Significance for South Sudan: Rick Simpson could not ship his oil anywhere—it was Schedule I, illegal kɛ̈ produce, possess, ku transport. Cancer patient in South Sudan, chronic pain patient in Kampala, ku veteran in Nairobi can now access same clinical-strength multi-cannabinoid RSO formula that Houston resident receives via same-day delivery. We built product that can move across borders legally, completing piece of Rick Simpson’s vision that prohibition made impossible during his lifetime.

Our PANDEM1C SEO technology—proprietary system with 14 million distinct geopolitical locations in its database ku over 300 AI models—drives organic search visibility across six continents, making our products discoverable kɛ̈ South Sudanese patients searching for RSO in English ku through translation tools.

How Our Formulas Connect kɛ̈ Evidence

Every cannabinoid in our formula—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, ku CBC—has its own evidence profile in our GENERAL KNOWLEDGE section. Every terpene—limonene, myrcene, caryophyllene, pinene, linalool, humulene, ku terpinolene—ee covered with preclinical ku review-level evidence.

Formulas published in this document are not standalone product listings. They ee anchored kɛ̈ per-compound evidence summaries explaining what ee well-supported by human clinical data, what ee emerging from review ku preclinical literature, ku what ee overstated relative kɛ̈ current evidence base. Where our RSO guide page makes specific research claims about individual cannabinoids ku terpenes, this document provides source evaluation context—same peer-reviewed citations, same evidence-tier assessments, ku same cautious interpretation framework.

Our evidence hierarchy, overstatement warnings, ku safety notes apply equally kɛ̈ our own products. We do not exempt ourselves from same evidence standards applied kɛ̈ broader cannabinoid field. That ee intentional. Our position—as stated by Colin Valencia in 2019—ee that people deserve best possible version of information so they can give it fair shot ku decide for themselves whether it ee right ku wrong for them.

For South Sudanese readers, this means you are not getting marketing hype. You are getting same level of scientific honesty we would give our own families.

Media Recognition: Independent Verification of Our Credibility

Colin Valencia—Houston’s Cannabis Authority

Between September 2019 ku April 2023, ABC13 Houston (KTRK)—ABC affiliate serving America’s fourth-largest city—featured Colin Valencia ku OilWell Cannabis in seven distinct news segments spanning business, law, medicine, community health, ku politics. Five different ABC13 reporters sought Colin out: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, ku KTRK staff writers. No other Houston cannabis operator appears with that frequency ku breadth during same period.

Features document consistent pattern. When ABC13 needed kɛ̈ explain new cannabis product, it called Colin. When state agency reversed course on Delta-8 legality overnight, it called Colin. When president announced marijuana pardons ku station needed someone who had personally lived with cannabis conviction kɛ̈ provide context, it called Colin. When station wanted kɛ̈ tell story of growing industry on 4/20, it was Colin’s hemp field ku Colin’s voice that anchored report.

Cienë level of mainstream media validation from major ABC affiliate establishes credibility that transcends geography. For South Sudanese customers evaluating online cannabis company from halfway around world, cienë independent verification matters. We are not fly-by-night operation. We are documented, legitimate business with track record of ethical leadership.

Complete ABC13 Feature Record

Feature 1: Texas CBD businesses booming (September 15, 2019)
Reporter: Tom Abrahams
Colin’s foundational quote: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

Cienë quote—our philosophical anchor—originates here. Video segment noted CBD was being pitched “for every member of family, including pets,” foreshadowing our broad-spectrum approach.

Feature 2: Entrepreneur creates direct-to-consumer business (March 22, 2021)
Reporter: Tom Abrahams
Colin provided ecosystem support kɛ̈ entrepreneur Jonathan Pina’s mobile vendor concept. Quote: “People think that everyone just wants to get high… But that’s a different version of therapy, and people are looking for things to help them with real pain. Pain comes in a lot of different forms.”

Feature 3: What is Delta 8 THC (May 24, 2021)
Reporter: Steve Campion
Iconic exchange:

• Campion: “Why would someone want to smoke that?”
• Colin: “I don’t give a sh** if it’s wrong to say you’ll get high off it. Maybe you want to get high.”

Cienë radical honesty on mainstream television—expletive preserved by network—became Colin’s most recognized moment. Piece balanced his stance with medical caution from Dr. Michael Weaver ku regulatory advocacy from Heather Fazio (Texans for Responsible Marijuana Policy), plus DEA statement.

Feature 4: Houston CBD shop giving away free products for COVID vaccine (August 20, 2021)
KTRK Staff
We donated approximately $35,000 in product (1,000 caviar pre-rolls at $34.99 each) kɛ̈ encourage COVID-19 vaccination. Hosted at HydroShack Hydroponics retail partner. We coordinated with City of Houston kɛ̈ amplify vaccination efforts, demonstrating community commitment with no political strings attached.

For South Sudanese readers, this shows our character: when public health crisis required action, we committed real product ku coordinated with city government.

Feature 5: Texas ban over Delta 8 (October 19, 2021)
Reporter: Shelley Childers
When Texas reclassified Delta-8 as Schedule I overnight, Colin had already removed all Delta-8 products from shelves before enforcement began—before most of industry even knew. Ye tried kɛ̈ spread word kɛ̈ other operators unknowingly shipping Schedule I narcotics.

Quote: “So those people are now, because they didn’t know, shipping Schedule 1 narcotics, and people are receiving it.”

Zachary Maxwell (Texas Hemp Growers) provided context: veterans with PTSD, $50 million Texas market, felony penalties for single vape cartridge.

Cienë demonstrated ethical leadership during regulatory crisis. We absorbed major revenue loss, acted proactively, ku positioned ourselves as expert guide for industry in crisis rather than victim of regulation.

Feature 6: Biden marijuana pardon (October 7, 2022)
Reporter: Nick Natario
We were preparing kɛ̈ debut CBD vending machine. Article revealed: Colin has previously faced charges for marijuana possession.

Quote: “You face challenges with housing, loans, and banking, I mean with about everything.”
Quote: “I would love to see people not get hurt for this anymore.”

Cienë personal revelation transforms our entire media record. Every feature, every quote about therapy ku education carries additional weight knowing Colin personally experienced cannabis criminalization consequences. For South Sudanese readers who have lived under repressive legal regimes, cienë creates deep resonance.

Feature 7: Marijuana industry getting creative (April 21, 2023)
Reporter: Nick Natario
Most recent feature, published day after 4/20. Colin’s “Renaissance” framing: “Right now is actually a pretty – like Renaissance – pretty important time that should be enjoyed now.”

Nico Richardson (Texas Original CEO) provided context: Texas has ~10,000 active medical marijuana patients vs. Florida’s 700,000 with two-thirds population. HB1805 expansion mentioned. $3.7 billion tax revenue from legal states cited.

From our first 2019 CBD business profile through Delta-8 boom/bust, COVID community initiative, personal revelation of conviction history, ku “Renaissance” framing—Colin’s media trajectory mirrors legal cannabis trajectory in America.

What This Media Record Means for South Sudan Customers

These seven ABC13 features ku one YouTube demonstrate:

• Consistency across years: We appeared in 2019, 2021 (four times), 2022, ku 2023 through every market shift
• Breadth of expertise: Business, consumer health, product investigation, legal analysis, political commentary, community advocacy
• Community action: $35,000 vaccine giveaway, proactive Delta-8 removal, warning other operators
• Personal stakes: Colin’s conviction history revealed, making every prior quote more powerful
• Evolution of language: From “CBD wholesaler” kɛ̈ “industry authority” kɛ̈ “sector leader”

These are not marketing materials. They are independently produced, editorially controlled news segments from major-market ABC affiliate that repeatedly identified Colin Valencia as most credible, quotable, accessible voice in Houston’s legal cannabis industry.

For South Sudanese customers evaluating us from thousands miles away, this ee third-party verification that we are real, legitimate, ethical, ku committed kɛ̈ community over profit. That recognition cannot be purchased—it can only be earned.

The Science Behind Our Formulas: General Knowledge

Research Method ku Evidence Weighting

We prioritize sources in this order: human clinical evidence, systematic reviews ku meta-analyses, NIH ku institutional summaries, then mechanistic ku preclinical literature when human data are sparse. Cienë weighting matters because evidence base ee not evenly distributed. Of compounds in our formulas, CBD ku delta-9 THC have strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, ku most terpenes ee still more dependent on reviews, animal work, ku in vitro pharmacology ku early translational literature [1]-[29].

Cienë approach ee essential for South Sudanese readers navigating landscape of conflicting health claims. We give you same standard of evidence evaluation we use for ourselves.

Institutional Baseline from NIH ku Related Sources

• NCCIH states strongest established cannabinoid evidence ee for certain rare epilepsies, chemotherapy-related nausea/vomiting, ku appetite/weight-loss indications associated with HIV/AIDS. Only modest evidence exists for chronic pain ku multiple-sclerosis symptoms, with many claimed uses still in early-stage research [1].
• FDA has not approved cannabis plant itself for medical use, although purified CBD ku synthetic THC-like drugs have specific approvals [1].
• Safety concerns highlighted by NIH include impairment, motor vehicle crash risk, cannabis use disorder, pregnancy concerns, accidental pediatric exposure, contamination, labeling inaccuracy, ku THC-vape lung-injury concerns [1].
• NCCIH warns over-the-counter CBD products may differ from labels ku that CBD itself has been associated with decreased alertness, gastrointestinal effects, liver-related adverse effects, ku drug interactions [1].

For South Sudanese customers, these safety considerations are especially important given limited access kɛ̈ emergency medical care. We emphasize responsible use ku clear labeling because your safety matters.

Cannabinoid Profiles: What Science Shows

CBD:

• Strongest evidence: Purified CBD has most credible human evidence in seizure disorders—clear major-example indication acknowledged by institutional ku peer-reviewed literature [1][2].
• Anxiety: 2024 systematic review ku meta-analysis covering 316 participants across eight articles reported statistically significant anxiolytic signal, but authors stressed clinical sample remains limited ku more trials needed [3].
• Pain: 2024 systematic review concluded pain literature ee promising but heterogeneous, with trial quality ku consistency limiting confidence in broad analgesic claims [4].
• Sleep: 2023 insomnia review found literature remains methodologically weak, with many studies relying on nonvalidated subjective measures ku few objective sleep assessments [5].
• Safety: 2023 systematic review ku meta-analysis found real signal for liver enzyme elevation ku possible drug-induced liver injury in some CBD contexts, especially relevant for concentrated oral products ku polypharmacy settings [6]. NCCIH flags diarrhea, sleepiness, appetite change, mood effects, liver-function abnormalities, ku drug-drug interactions [1].
• Bottom line: CBD ee most evidence-developed nonintoxicating cannabinoid, but strong evidence ee concentrated in few specific indications rather than broad wellness claims [1]-[6].

CBG:

• Evidence: Mostly review-level ku preclinical; human evidence sparse [7][8].
• Pharmacology: CBG ee biosynthetic precursor kɛ̈ several major cannabinoids with pharmacologically distinct properties. Review literature describes interactions spanning cannabinoid receptors, alpha-2 adrenoceptors, ku 5-HT1A-related signaling—mechanistically interesting but not yet clinically established [7].
• Research areas: Reviews discuss possible relevance kɛ̈ neurologic disorders, inflammatory bowel disease, ku antibacterial activity, but these are primarily pharmacology-led hypotheses ku preclinical findings rather than mature human therapeutic conclusions [7][8].
• Caution: 2021 pharmacology review notes CBG ee already being sold commercially while evidence base remains thin, meaning claims frequently outrun science [7].
• Bottom line: CBG ee serious research topic but should be described as promising minor cannabinoid with limited clinical validation rather than proven therapeutic [7][8].

Delta-8 THC:

• Evidence: Pharmacologically relevant, psychoactive, much less clinically characterized than delta-9 THC [9]-[11].
• Comparative pharmacology: 2022 review concluded delta-8 THC ku delta-9 THC have broadly similar pharmacokinetic ku pharmacodynamic behavior. Delta-8 THC ee partial CB1 agonist with cannabimimetic activity in animals ku humans, but appears less potent than delta-9 THC, likely due kɛ̈ weaker CB1 affinity [9].
• Public health: 2023 scoping review found delta-8 evidence base dominated by animal studies, product chemistry, use reports, ku public-health concerns rather than strong modern human trials. Review noted reports of adverse consequences ku emphasized regulatory ku product-quality concerns [10].
• Manufacturing: 2024 chemistry ku pharmacology review reinforces commercial delta-8 interest tied kɛ̈ greater stability ku easier synthesis relative kɛ̈ naturally scarce plant levels, which ee why product-byproduct ku lab-testing questions matter [11].
• Bottom line: Delta-8 THC should be treated as psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, ku more manufacturing-quality uncertainty than many consumers realize [9]-[11].

THCa:

• Evidence: Important chemically ku formulation-wise, but still low on direct human therapeutic evidence [12].
• What it ee: THCa ee acidic precursor of THC ku may represent large share of THC-related content in raw plant material. Key formulation issue: THCa decarboxylates into THC during heating ku can change over time during storage ku processing [12].
• Psychoactivity: Major review source stresses THCa itself does not produce psychoactive effects associated with THC in humans, but distinction only holds if molecule stays in acidic form ku ee not substantially decarboxylated [12].
• Research status: In vitro ku rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, ku antineoplastic possibilities, but these are not equivalent kɛ̈ established human outcomes [12].
• Bottom line: THCa ee best understood as highly relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, ku storage. Any claim about THCa needs kɛ̈ account for possible conversion into THC [12].

Delta-9 THC:

• Evidence: Strongest human evidence of psychoactive cannabinoids listed, but also clearest adverse-effect burden [1][13]-[15].
• Institutionally best supported: NCCIH identifies THC-containing cannabinoid medicines as relevant kɛ̈ chemotherapy-related nausea/vomiting, appetite/weight loss in HIV/AIDS, ku some multiple-sclerosis- ku pain-related outcomes, while stressing many other uses remain uncertain ku early-stage [1].
• Pain evidence: 2022 systematic review of cannabis-based products for chronic pain found products with high THC content ku comparable THC:CBD ratios may provide short-term pain benefit, but also increased dizziness, sedation, nausea, ku treatment discontinuation due kɛ̈ adverse events [13].
• Pharmacokinetics: Classic review literature remains useful: inhaled THC produces effects within seconds kɛ̈ minutes, peaks roughly within 15-30 minutes, tapers over few hours; oral THC has later onset, later peak, longer duration—matters for both benefit ku overconsumption risk [14].
• Mental health risk: 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis/schizophrenia outcomes ku cannabis use disorder, with concerning signals for anxiety ku depression in nontherapeutic settings [15].
• Broader safety: Institutional ku review literature describe anxiety/panic at high doses, tachycardia, blood-pressure changes, dependency potential, withdrawal symptoms, pregnancy concerns, accidental pediatric exposure, ku vape-related lung-injury concerns [1][14][15].
• Bottom line: Delta-9 THC has legitimate therapeutic relevance in some settings but carries clearest intoxication, psychiatric, ku dose-related safety liabilities in this document [1][13]-[15].

CBN:

• Evidence: Weak human evidence; marketing clearly moved ahead of data [12][16][17].
• What marketed for: Sleep ku sedation. Reputation ee widespread, but clinical support far thinner than market suggests [16][17].
• Best direct review for sleep claim: 2021 narrative review on CBN ku sleep screened 99 human-study abstracts, reviewed eight full-text articles, found no clinical trials using validated sleep questionnaires ku formal polysomnography that could substantiate strong sleep-promoting claims for CBN [16].
• Broader sleep literature: 2024 updated review on cannabis ku sleep concluded overall cannabinoid sleep research still does not match scale of real-world use, ku need for better-designed, adequately powered trials remains substantial [17].
• Chemical context: Review literature on THCa notes THC can further degrade toward CBN under certain conditions, explaining why CBN ee often discussed in aging ku oxidized cannabis chemistry contexts [12].
• Bottom line: CBN ee clearest example in this field where cultural reputation ee stronger than current clinical evidence base [16][17].

CBC:

• Evidence: Emerging, intriguing, still overwhelmingly preclinical ku review-based [18][19].
• Pharmacology ku therapeutic interest: 2024 focused review on CBC argues it has distinct pharmacodynamics, pharmacokinetics, ku receptor behavior relative kɛ̈ better-known cannabinoids, ku highlights antinociceptive, antibacterial, ku anti-seizure areas as especially interesting research targets [18].
• Older literature: Review literature summarizing CBC in animal ku in vitro work reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, ku possible neurobiological ku antiproliferative relevance, but these signals are not yet strong evidence for patient-facing claims [19].
• Safety caveat: 2024 CBC review explicitly notes over-the-counter CBC products are already being sold despite little evidence establishing clinical efficacy ku safety [18].
• Bottom line: CBC belongs in category of scientifically credible minor cannabinoids that deserve more research, not category of already-validated clinical actives [18][19].

Terpene Profiles: The Aromatic Dimension

Terpene claims need even stricter interpretation than cannabinoid claims. Much literature comes from isolated compounds, essential oils, non-cannabis plants, ku preclinical models rather than controlled human studies of cannabis formulations. 2024 entourage-effect review makes this especially important: terpene bioactivity ee plausible ku sometimes compelling, but robust proof of clinically meaningful entourage effects in humans remains limited [20][29].

Limonene:

• Evidence: Largely review ku preclinical, useful safety literature [20]-[22].
• Potential activity: 2021 review describes limonene as multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory, ku other possible activities, but overwhelming share of claims comes from nonhuman ku non-cannabis literature [21].
• Safety note: Limonene oxidation products, especially hydroperoxides, ee clinically relevant contact allergens important in patch-testing literature [22].
• Bottom line: Limonene ee biologically active ku widely discussed, but cannabis-specific therapeutic claims should stay conservative unless directly supported in humans [20]-[22].

Myrcene:

• Evidence: Mostly preclinical, very limited human evidence [20][23].
• Research summary: 2021 myrcene review describes anxiolytic, antioxidant, anti-inflammatory, ku analgesic properties ku discusses possible mechanisms, but explicitly states human studies are lacking [23].
• Interpretation caution: Myrcene ee often invoked in consumer language as if it were proven sedating terpene explaining couch-lock or sleep effects. That ee stronger claim than human evidence currently supports [20][23].
• Bottom line: Myrcene ee plausible bioactive terpene, but compound-specific clinical claims about mood, pain, ku sedation remain far ahead of definitive human proof [23].

Caryophyllene:

• Evidence: Among most mechanistically interesting terpenes because of direct cannabinoid-system relevance, but still mostly preclinical [24].
• Why it stands out: 2021 focused review describes beta-caryophyllene as selective CB2 receptor agonist, unusual ku especially relevant when discussing cannabis terpenes in pharmacologic rather than purely aromatic terms [24].
• Research themes: Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective, ku related actions repeatedly discussed in review literature, but human clinical confirmation remains limited [24].
• Bottom line: Beta-caryophyllene ee arguably strongest candidate for terpene with cannabinoid-system significance, but still should not be described as clinically proven for outcomes commonly attributed to it [24].

Pinene:

• Evidence: Promising preclinical literature, weak human clinical confirmation [20][25].
• Brain-health framing: 2021 review on pinene ku linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, ku neuroprotective signals justifying future study, but emphasized evidence ee mostly preclinical ku well-designed clinical trials are lacking [25].
• Interpretation caution: Claims that pinene reliably improves memory, sharpens attention, ku counterbalances THC-related cognitive effects remain interesting hypotheses rather than settled clinical facts [20][25].
• Bottom line: Pinene deserves scientific attention, but strong cognition-related claims should be presented as exploratory [25].

Linalool:

• Evidence: Substantial preclinical interest, limited direct clinical confirmation [20][22][25][26].
• Research summary: Linalool repeatedly discussed in relation kɛ̈ stress, mood, ku brain-health pharmacology. 2021 brain-health review found enough preclinical signal kɛ̈ justify continued investigation in neurological ku psychiatric contexts, while still emphasizing lack of robust human trials [25].
• Additional literature: Separate review literature discusses possible antidepressant mechanisms ku neuropharmacologic relevance, but this remains translational rather than definitive clinical story [26].
• Safety note: As with limonene, oxidized linalool hydroperoxides ee recognized allergens in dermatitis literature [22].
• Bottom line: Linalool ee scientifically credible as bioactive terpene, but current evidence supports cautious phrasing rather than firm therapeutic promises [22][25][26].

Humulene:

• Evidence: Translationally interesting, but still early [20][27].
• Scoping-review findings: 2024 scoping review analyzed 340 articles ku found broad preclinical evidence for anti-inflammatory ku other biologic effects, with some rodent work even suggesting cannabimimetic properties via CB1 ku adenosine A2a pathways [27].
• Interpretation caution: Those findings are valuable for hypothesis generation, but do not yet establish consistent human efficacy across pain, inflammation, ku mood outcomes [27].
• Bottom line: Humulene ee one of more interesting terpene research targets in this list, but remains far from clinically settled [27].

Terpinolene:

• Evidence: One of least clinically characterized terpenes in this file [20][28].
• Systematic-review findings: 2021 terpinolene review screened 2,449 records ku included 57 studies, concluding terpinolene has range of reported biological effects but evidence base ee still dominated by in silico, in vitro, ku animal studies rather than human trials [28].
• Interpretation caution: Even recent cannabis entourage reviews frame terpene benefits as exploratory, not as established compound-specific clinical effects [20].
• Bottom line: Terpinolene ee biologically interesting, but among listed terpenes remains especially underdeveloped clinically [20][28].

Research Limits ku Common Overstatements kɛ̈ Avoid

Research limits:

• Evidence base ee highly uneven. CBD ku delta-9 THC can support most detailed human-facing statements; rest require more caution [1]-[29].
• Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, ku terpene-only data are not interchangeable. Common error in cannabis writing ee letting evidence from one category stand in for another.
• Minor cannabinoids ku terpenes are commercially interesting precisely because they are underexplored, but that also means claims around them often become inflated.
• Product quality matters as much as molecule identity. In South Sudan’s climate, labeling inaccuracies, contamination, synthesis byproducts, dose variability, ku route-dependent pharmacokinetics all materially affect real-world products [1][10][11][14].
• For THCa, chemistry ee destiny: storage ku heating can change actual exposure profile by converting acidic cannabinoids into neutral cannabinoids such as THC [12].

Common overstatements kɛ̈ avoid:

• Overstatement: CBN ee clinically proven sleep cannabinoid.
  More accurate: Specific sleep evidence for CBN remains weak ku dated, with no strong validated-trial base yet identified [16][17].
• Overstatement: Myrcene ee proven human sedative that reliably explains couch-lock.
  More accurate: Myrcene has plausible preclinical bioactivity, but direct human proof for common claim ee limited [20][23].
• Overstatement: Terpenes in general have proven entourage effects in patients.
  More accurate: Entourage hypotheses are influential ku worth studying, but robust clinical proof remains limited ku highly compound-specific [20][29].
• Overstatement: THCa ee always nonpsychoactive.
  More accurate: THCa itself ee not THC, but heating ku processing can convert THCa into THC, changing effective exposure [12].
• Overstatement: Delta-8 THC ee safe because it ee hemp-derived.
  More accurate: Delta-8 THC ee psychoactive, pharmacologically close kɛ̈ delta-9 THC, ku often entangled with manufacturing ku testing concerns [9]-[11].

Practical Takeaways for Our South Sudan Formulas

• Most evidence-developed actives: CBD ku delta-9 THC
• Delta-8 THC ee not trivial ku purely mild ingredient; it ee psychoactive cannabinoid with less robust safety ku efficacy characterization than delta-9 THC
• THCa meaningfully changes with processing ku should not be interpreted same way in raw, gently handled, ku heated formats
• CBG, CBN, ku CBC are scientifically credible but clinically immature compared with CBD ku THC
• Listed terpenes likely highly relevant kɛ̈ aroma, flavor, ku potentially some biologic activity, but compound-specific human therapeutic claims should be made carefully ku only where directly supported
• For South Sudanese users: these products are tools for wellness, not replacements for proven medical treatments. Use them as part of informed health strategy, not as sole intervention for serious conditions.

Our Complete Formulas: Transparency for South Sudan

RSO Sublingual Oil Formula

Cannabinoid	Amount (mg)	% of Total
CBD	4,500	27.1%
CBG	3,000	18.1%
Delta-8 THC	6,000	36.2%
THCa	1,500	9.0%
Delta-9 THC	90	0.5%
CBN	750	4.5%
CBC	750	4.5%
Total	16,590 mg	100%

• Live Terpenes: 5% (1500 mg total)
  • Limonene: citrus-bright aroma
  • Myrcene: earthy base note
  • Caryophyllene (β-caryophyllene): pepper/spice
  • Pinene: forest-fresh
  • Linalool: floral, lavender
  • Humulene: earthy, woody
  • Terpinolene: piney, fruity, sparkling
• Carrier: Organic MCT oil
• Volume: 30 mL (1 fl oz)
• Active cannabinoids per mL: 553 mg
• Price: $129.99 USD
• Shipping kɛ̈ South Sudan: Available with full documentation; contact for customs guidance

RSO Vape Cartridge Formula

Cannabinoid	Percentage	mg per gram
CBD	30%	300 mg
CBG	20%	200 mg
Delta-8 THC	15%	150 mg
THCa	10%	100 mg
CBN	10%	100 mg
CBC	10%	100 mg
Total	95%	950+ mg

• Live Terpenes: 5%+ (50+ mg)
• Format: 1-gram 510-thread cartridge
• Price: $49.99 USD
• Battery: Universal 510-thread (widely available in South Sudan’s electronics markets)
• Shipping kɛ̈ South Sudan: Available; temperature-stable packaging ensures product integrity during transport

Terpene Profile Details for South Sudan Users

Both products contain same seven-terpene profile at 5% concentration:

Limonene (citrus-bright): Common in citrus peels, familiar kɛ̈ South Sudanese who enjoy imported oranges ku lemons. Associated with mood elevation in preclinical studies [21].

Myrcene: Earthy base note found in mangoes (common in South Sudan). Preliminary research suggests possible sedative properties, though human evidence remains limited [23].

Caryophyllene (β-caryophyllene): Pepper/spice aroma. Unique as dietary cannabinoid that directly activates CB2 receptors, offering anti-inflammatory potential without psychoactivity [24].

Pinene (forest-fresh): Pine aroma. Traditional medicine systems worldwide use pine for respiratory support. Preclinical research suggests possible airway benefits [25].

Linalool (floral, lavender): Lavender scent familiar from imported soaps ku oils. Widely used in aromatherapy for calm; preclinical evidence supports anxiolytic potential [26].

Humulene (earthy, woody): Found in hops ku traditional herbs. Preclinical research shows anti-inflammatory properties [27].

Terpinolene (piney, fruity, sparkling): Complex aroma profile. Least clinically studied of our terpenes, but contributes kɛ̈ entourage effect potential [28].

For South Sudanese users, these aromas connect kɛ̈ familiar scents from local markets, imported goods, ku traditional medicine practices, making product experience more culturally accessible.

Conclusion: Our Commitment kɛ̈ South Sudan

OilWell Cannabis ee more than brand—we are promise kɛ̈ our customers that we will always strive kɛ̈ deliver best, most thoughtful cannabis products available. We are not here kɛ̈ follow trends. We are here kɛ̈ set them through evidence-based formulation, radical transparency, ku community commitment.

From Houston, Texas kɛ̈ Juba, South Sudan, we bring same standard: make products with intent, answer directly, ku never pretend cannabis ee right for everyone. We understand that in South Sudan, where healthcare infrastructure has been devastated by conflict ku economic challenges, people need options they can trust.

Our formulas work because they were born from love—Bentley’s ten-year journey from paralysis kɛ̈ natural death at twenty, Colin’s battle with PTSD ku benzo addiction, ku thousands of hours of research. Every milligram in our bottles serves purpose. Every terpene was chosen deliberately. Every safety test was run because your wellbeing matters more than our profit.

We ship kɛ̈ South Sudan because Rick Simpson’s vision of accessible cannabis medicine should not be limited by geography. We publish our formulas because economic justice matters. We test every batch because your safety ee non-negotiable. We tell truth about evidence because informed decisions are only ones worth making.

Ready kɛ̈ order for South Sudan delivery?

• Website: https://oilwellcbd.com/thca-rick-simpson-oil-rso-by-oilwell-cannabis-of-houston-texas/
• Email: [email protected]
• Phone: +1 (832) 416-2816 (WhatsApp available for international customers)
• Instagram: @oilwellcbd

We answer every question. We provide COAs for every batch. We ship with full documentation. Ku we stand behind every product with integrity that earned us ABC13’s trust across seven features ku four years.

From our family kɛ̈ yours in South Sudan: this ee healing, open-sourced. This ee medicine, democratized. This ee future Rick Simpson imagined, made real through science, made accessible through global shipping, made trustworthy through transparency.

Order today. Heal tomorrow. Questions welcome.

ENGLISH

Rick Simpson Oil (RSO) in South Sudan: The Complete Guide by OilWell Cannabis

Understanding RSO: From Nova Scotia to South Sudan

Who Was Rick Simpson, and Why His Story Matters Here

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He wasn’t a doctor, scientist, or medical researcher. He was a power engineer and maintenance worker—a tradesman whose journey into cannabis advocacy began with personal suffering and a medical system that failed him. This story resonates powerfully across South Sudan, where many communities have experienced firsthand what it means when conventional medicine falls short.

In 1997, while working at a hospital in Moncton, New Brunswick, Simpson fell from scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and post-concussion symptoms that conventional medicine couldn’t resolve. The medications prescribed either didn’t help or made his condition worse. When cannabis provided more relief than anything his doctors offered, his physician refused to support or prescribe it. This pattern of pharmaceutical failure followed by dismissal is one we hear about regularly from customers reaching us from Juba, Wau, Malakal, and rural communities across South Sudan.

Simpson’s interest in concentrated cannabis oil deepened after learning about a 1974 study at the Medical College of Virginia, funded by the National Institute of Health, where THC was reported to slow or shrink tumors in mice. That study—originally intended to demonstrate harm—became foundational to Simpson’s advocacy, even though its findings were never replicated in controlled human cancer trials.

The pivotal moment came in 2003. Three bumps on his arm were diagnosed as basal cell carcinoma. Rather than pursuing conventional treatment, Simpson applied concentrated cannabis oil directly to the lesions, covered them with bandages, and waited. According to his account, the bumps disappeared within four days. No independent medical verification has been published, and no biopsy confirmation exists in any peer-reviewed source. Yet this personal experience became the origin story of Rick Simpson Oil.

Important context for South Sudan readers: Simpson’s account is personal testimony, not medical evidence. The absence of clinical documentation means these events cannot be evaluated as scientific proof. However, they are historically significant as the catalyst for a global movement—one that has now reached South Sudan, where traditional medicine practitioners and modern clinicians alike are exploring cannabis extracts.

The Crusade: Spreading the Oil Across Continents

After his 2003 experience, Simpson committed himself to producing and distributing concentrated cannabis oil. Operating from his property in Maccan, Nova Scotia, he made oil in large quantities and gave it away free to cancer patients and others. He charged nothing. By his account, he helped dozens of people with conditions including cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, and insomnia—conditions that affect families throughout South Sudan.

Simpson’s story reached a global audience through the 2005 documentary Run From The Cure, directed by Christian Laurette. The film documented his claims, showed testimonials, and framed his work as a grassroots challenge to pharmaceutical interests. Distributed freely online, it became one of the most widely shared cannabis advocacy films and introduced concentrated cannabis oil to millions—including many in Africa who would later seek out RSO.

Simpson’s advocacy brought him into direct conflict with Canadian law. The Royal Canadian Mounted Police raided his property in 2005 and 2009. He was charged with cultivation, possession, and trafficking. Facing continued legal pressure, Simpson eventually left Canada for Europe, living in Croatia and later the Netherlands, where he continued his advocacy from abroad.

In 2012, he published Phoenix Tears: The Rick Simpson Story, detailing his experience, oil-making process, and philosophical views. He maintained phoenixtears.ca as his primary platform for information and advocacy.

Throughout his public career, Simpson maintained an uncompromising position: cannabis oil—particularly high-THC oil made according to his method—could cure cancer and many other diseases. He claimed pharmaceutical companies, government agencies, and medical institutions were actively suppressing this knowledge to protect financial interests. He framed his work as fighting institutional corruption.

Important context for South Sudan readers: Simpson’s conspiratorial worldview reflects a perspective shared by many in the early cannabis movement, especially those who faced legal persecution. In South Sudan, where institutional trust has been fractured by decades of conflict, this framing resonates with many who have seen resources flow to elites while communities suffer. However, understanding the evidence requires moving beyond worldview to examine what science actually shows.

The Traditional RSO Protocol: Understanding the 60-Gram Regimen

Simpson’s core treatment recommendation was a structured oral protocol delivering 60 grams (approximately 60 mL) of concentrated cannabis oil over roughly 90 days. He described this as a cancer treatment protocol, though he recommended it for numerous conditions. Here is the detailed breakdown as Simpson described it:

Goal: Consume 60 grams of concentrated, high-THC cannabis oil over approximately 90 days. Simpson considered this the minimum necessary for a serious cancer treatment course.

Titration schedule:

• Week 1: Begin with a dose the size of half a grain of dry rice—roughly 10-15 milligrams of oil—taken three times daily. Total daily intake: approximately 30-45 milligrams.
• Weeks 2-5: Double the dose approximately every four days to build THC tolerance gradually and minimize psychoactive disruption. By the end of five weeks, reach approximately 1 gram (1,000 milligrams) of oil per day, divided into three roughly equal doses.
• Weeks 5-12: Maintain 1 gram per day, divided into three doses of roughly 333 milligrams each, until the full 60 grams are consumed.

Administration methods:

• Primary—oral: Place the dose under the tongue (sublingual) or swallow it. Simpson considered oral ingestion essential for systemic absorption and the primary method for internal cancers.
• Secondary—topical: For skin cancers and external lesions, apply oil directly to the area, cover with a bandage, and change every 3-4 days. Simpson combined topical application with oral dosing for skin cancers.
• Not recommended—primary inhalation: Simpson did not recommend smoking or vaporizing oil as a primary treatment method. He acknowledged inhalation for immediate symptom relief (pain, nausea) but maintained that oral route was necessary for sustained, high-dose exposure.

Tolerance and psychoactive effects: Simpson maintained patients develop significant tolerance to THC’s psychoactive effects within 3-4 weeks. He considered euphoria, sedation, or disorientation minor and temporary, urging patients not to let the high discourage continuation. He recommended initial doses at night to sleep through the most intense effects and warned against driving or operating machinery during titration. He also advised informing family members about what to expect.

Post-protocol maintenance: After completing the 60-gram course, Simpson recommended a maintenance dose of 1-2 grams of oil per month, taken indefinitely. He considered this ongoing low-dose maintenance important for long-term health and cancer prevention.

Dietary and lifestyle recommendations: Simpson advocated for dietary changes alongside the oil protocol, including reducing sugar, avoiding processed foods, and improving overall nutrition. This was secondary and general compared to his highly detailed oil protocol.

Important context for South Sudan readers evaluating this protocol: This protocol was designed by one person based on personal experience and anecdotal observations, not clinical trials. Critical points:

• No controlled trial validation exists. No published randomized controlled trials, cohort studies, or well-documented case series evaluate this specific 60-gram/90-day protocol for any cancer type or condition.
• It assumes crude, unstandardized material with no standardized potency. Actual THC content per gram of traditional RSO varied widely.
• Very high THC exposure: At peak dosing, patients consumed roughly 1 gram of high-THC oil daily. Assuming 60-90% THC content, this translates to 600-900 milligrams of delta-9 THC per day—a dose far exceeding anything studied in controlled clinical settings. For context, FDA-approved synthetic THC drug dronabinol is typically dosed at 2.5-20 milligrams per day.
• Real risks at these doses: Consuming 600-900 milligrams of THC daily carries serious risks including severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder. These risks are well-documented in the GENERAL KNOWLEDGE section [1][13][14][15].
• Oncology context: Patients with active cancer are medically complex. Using unregulated, unstandardized cannabis oil as primary cancer treatment—potentially in place of proven therapies—introduces harm extending beyond the oil itself.

What Traditional RSO Was as a Product

Traditional RSO refers to the specific concentrated cannabis oil Simpson made and advocated for, defined by his method and materials—not lab specifications or regulatory standards.

Source material: Simpson used high-THC, indica-dominant cannabis strains. He favored heavy, sedating indica genetics and generally recommended against sativa for cancer treatment. He grew his own cannabis or sourced from trusted growers. There was no strain standardization—starting material varied by availability and growing season. In South Sudan, where agricultural conditions differ dramatically from Nova Scotia, this variability would be even more pronounced.

Extraction solvent: Simpson originally used naphtha—a petroleum-based solvent commercially available as lighter fluid. He later endorsed 99% isopropyl alcohol as an alternative. He warned against butane or acetone. Neither naphtha nor isopropyl alcohol is food-grade, creating significant safety concerns. In South Sudan’s climate, solvent evaporation and safety handling would present additional challenges.

Extraction process:

1. Dry or semi-dry cannabis placed in a container (typically a bucket)
2. Covered with solvent and agitated for several minutes to dissolve cannabinoids
3. Poured through filter (cheesecloth) into collection vessel
4. Repeated with fresh solvent on same plant material
5. Combined solvent washes placed in rice cooker
6. Solvent evaporated at relatively low heat—sufficient to decarboxylate THCa into THC and destroy most volatile terpenes
7. Thick, dark oil remained at bottom
8. Final oil transferred to oral syringes

Appearance and physical characteristics: Traditional RSO was nearly black, thick, viscous, tar-like oil with strong cannabis odor and possible solvent-residual smell. The consistency was sticky and difficult to handle at room temperature but became more fluid when warmed slightly.

Cannabinoid profile:

• Primarily decarboxylated delta-9 THC—heat converted essentially all THCa
• Naturally occurring minor cannabinoids (CBD, CBN, CBC, CBG) present at natural ratios, but not controlled, measured, or targeted
• No ratio control—profile entirely determined by source plant genetics and growing conditions
• Estimated THC content: 60-90% total THC by weight, never lab-verified

Terpene content: Minimal to none. Solvent extraction dissolved terpenes, and high-heat evaporation volatilized them at temperatures below cannabinoid degradation thresholds. Traditional RSO was effectively stripped of terpene content.

Standardization and testing: None. Every batch differed based on plant material, growing conditions, solvent purity, extraction technique, evaporation temperature/duration, and maker’s process. No Certificate of Analysis, cannabinoid quantification, or contaminant screening existed. Simpson operated before cannabis legalization and standardized lab-testing infrastructure.

Residual solvent risk: This is one of the most significant safety concerns. Naphtha is a complex petroleum hydrocarbon mixture that may contain benzene, toluene, xylene, and other toxic/carcinogenic compounds. Incomplete solvent purging—very difficult to verify without analytical chemistry equipment—leaves potentially harmful residues. Modern extraction uses food-grade ethanol or supercritical CO₂ specifically to address this problem.

Simpson’s Claims vs. The Evidence Record

Rick Simpson made expansive therapeutic claims: RSO could cure cancer (including terminal cases) and was effective against diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, multiple sclerosis, and more. He was adamant, consistent, and public about these claims throughout his advocacy career.

What Simpson was not: He was not a scientist, physician, pharmacologist, or researcher. He had no formal training in medicine, oncology, pharmacology, or clinical research methodology. He never designed, conducted, funded, or published a clinical trial. He never submitted results to peer review. His evidence base consisted of personal experience, self-reported patient outcomes, and informally gathered testimonials—with no controls, independent verification, imaging confirmation, long-term follow-up, or blinding.

What the preclinical literature shows: The cannabinoid-cancer literature does exist and is scientifically interesting:

• In vitro studies demonstrate THC and CBD can induce apoptosis, inhibit proliferation, and reduce angiogenesis in certain cancer cell lines
• Animal model studies show some tumor-growth inhibition in mice and rats
• These findings generate legitimate scientific interest and ongoing research

What the preclinical literature does NOT show:

• These findings have not translated into proven human cancer cures. The gap between in vitro/animal results and human clinical outcomes is vast and well-documented across oncology research
• No human clinical trial has demonstrated RSO or any cannabis oil preparation cures cancer
• Several small human trials of cannabinoids in cancer contexts (particularly glioblastoma) have been exploratory, small, and have not produced results supporting cancer-cure claims

Institutional positions:

• U.S. National Cancer Institute (NCI) acknowledges cannabinoids have been studied for potential anticancer effects in lab and animal models but does not endorse cannabis or cannabis oil as cancer treatment
• FDA has not approved any cannabis plant product for cancer treatment. Only FDA-approved cannabinoid-related products are for other specific indications: Epidiolex (CBD) for certain seizure disorders and dronabinol/nabilone (synthetic THC analogues) for chemotherapy-related nausea and AIDS-related wasting
• Health Canada has never approved RSO or cannabis oil as cancer cure
• NCCIH explicitly states strongest cannabinoid evidence is for rare epilepsies, chemotherapy-related nausea/vomiting, and appetite-related indications in HIV/AIDS—not cancer cure

What Simpson got right: He drew attention to cannabinoids as a serious biomedical research area when most of the world ignored or suppressed that conversation. His advocacy—however scientifically imprecise—helped create political, cultural, and social conditions for the legal cannabis industry and cannabinoid research infrastructure that exists today. He was among the first to bring concentrated cannabis oil to widespread public awareness, and the term RSO remains the most recognized name for full-spectrum cannabis extract in consumer vocabulary. These contributions are real and historically significant.

What he overstated: The leap from preclinical signals to cancer cure was not supported by human evidence when Simpson made it, and it is not supported now. Encouraging patients—particularly cancer patients—to rely on RSO as primary treatment in place of proven oncologic therapies (surgery, radiation, chemotherapy, immunotherapy) carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern in alternative-medicine literature. Simpson’s absolute certainty about curative claims exceeded what the evidence could support and still exceeds it today.

The Legacy and Evolution of Modern RSO

The term RSO is now used broadly and loosely across the legal cannabis industry. Many products labeled RSO bear little resemblance to what Simpson originally made. In dispensaries today, RSO can refer to almost any full-spectrum cannabis extract sold in syringe format, regardless of extraction method, cannabinoid profile, terpene content, or intended use. The term has become generic.

Simpson himself has been critical of commercial products using the RSO name while departing significantly from his original method and philosophy. He has publicly stated many products sold as RSO do not meet his standards and that commercialization contradicts his original intent. Simpson’s model was explicitly anti-commercial—he gave oil away free and urged others to make their own rather than buy from companies.

This philosophical tension is worth acknowledging. Simpson believed in a do-it-yourself, free-access model where anyone could grow cannabis, extract oil, and treat themselves without corporate or governmental intermediaries. The modern cannabis industry has done something very different: commercialized, standardized, and regulated what Simpson distributed for free. Whether that evolution represents improvement (quality control, lab testing, dosing precision) or betrayal (profit extraction, regulatory gatekeeping) depends on perspective, and the cannabis community remains divided.

What is not disputed is that modern RSO has evolved substantially from its origins, and those changes are directly relevant to the formulas in this document.

Traditional RSO vs. Modern Formulated RSO

Dimension	Traditional RSO	OilWell Formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None—every batch different	Lab-tested with specific mg/mL targets (553 mg/mL)
Lab testing	Not available or performed	Full panel testing (potency, terpenes, pesticides, heavy metals, residual solvents, microbial)
Residual solvents	Significant risk with naphtha	Controlled and tested—solvent-free production
Dosing precision	Approximate, syringe-based	Measured per mL with known cannabinoid content
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	No—fully decarboxylated by heat	Yes—THCa included as separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted with peer-reviewed citations
Accessibility	Illegal to produce/ship	Farm Bill compliant, ships to South Sudan with proper documentation

Why OilWell’s Formulas Diverge from Traditional RSO

Our formulations are not traditional RSO. They are informed by the RSO tradition but depart deliberately in evidence-motivated ways that solve problems limiting Simpson’s original vision:

Multi-cannabinoid approach. Traditional RSO relied on whatever single strain the maker grew or sourced. Our formulas intentionally include seven cannabinoids—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—because the entourage-effect literature suggests potential benefit from cannabinoid diversity, even though robust clinical proof of whole-formula synergy remains limited [20][29]. In South Sudan, where patients often face multiple concurrent health challenges, this multi-pathway approach may be particularly relevant.

Terpene preservation and addition. Traditional RSO had essentially no terpene content due to solvent and heat destruction. We include live terpenes at 5% with a specific seven-terpene profile—limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene—because terpene bioactivity is plausible and supported at the preclinical level, even if human clinical confirmation for cannabis-specific terpene effects is still developing [20][21][23][24][25][26][27][28][29]. The aromatic profile also makes the product more palatable for South Sudanese users accustomed to herbal medicines.

THCa as a separate ingredient. Traditional RSO fully decarboxylated everything, converting all THCa into delta-9 THC. Our sublingual formula includes THCa at 1,500 mg as a distinct ingredient, preserving the acidic precursor because the THCa literature suggests potentially relevant non-psychoactive bioactivity that is lost when THCa converts to THC [12]. This is crucial for South Sudanese patients who need daytime relief without impairment.

Reduced delta-9 THC dominance. Traditional RSO was 60-90% delta-9 THC. Our sublingual formula uses delta-9 THC at only 90 mg while incorporating delta-8 THC at 6,000 mg and distributing remaining cannabinoid content across CBD (4,500 mg), CBG (3,000 mg), CBN (750 mg), and CBC (750 mg). This reflects the broader cannabinoid research landscape rather than single-compound dominance.

Product format innovation. Simpson envisioned only one format: oral oil from a syringe. We offer both a 30 mL sublingual oil and a 1-gram vape cartridge, each with format-specific formulation acknowledging that different delivery routes have different pharmacokinetic profiles [14]. For South Sudan’s diverse geography—from urban Juba to remote rural areas—having multiple format options matters.

Solvent Safety and Extraction Evolution

Traditional RSO production used naphtha or isopropyl alcohol—neither food-grade. Naphtha is a complex petroleum hydrocarbon mixture that may contain benzene, toluene, xylene, and other toxic/carcinogenic compounds. Incomplete solvent purging—very difficult to verify without analytical chemistry equipment—leaves potentially harmful residues in finished oil.

Modern cannabis extraction overwhelmingly uses food-grade ethanol or supercritical carbon dioxide (CO₂). These methods allow much more complete solvent removal, and finished products can be tested for residual solvents using validated analytical methods like headspace gas chromatography. This is one of the most straightforward improvements the modern regulated cannabis industry has made over traditional RSO production.

This evolution connects directly to product-quality discussion in our GENERAL KNOWLEDGE section, which emphasizes that product quality matters as much as molecule identity and that labeling inaccuracies, contamination, synthesis byproducts, and dose variability all materially affect interpretation in real-world products [1][10][11][14].

The Decarboxylation Question

Traditional RSO was fully decarboxylated. The heat involved in evaporating solvent from the rice cooker—typically sustained at or near the solvent’s boiling point (60-80°C for naphtha, 82°C for isopropyl alcohol)—was sufficient to convert essentially all THCa in the extract into delta-9 THC. As a result, the acidic cannabinoids that exist abundantly in raw cannabis—THCa, CBDa, CBGa, and others—were lost as distinct compounds.

Our sublingual formula deliberately preserves THCa at 1,500 mg as a separate ingredient. This intentional formulation choice is informed by the THCa evidence profile, which notes that THCa itself does not produce psychoactive effects associated with THC, but its interpretation depends on route, temperature, processing, and storage—because THCa can convert to THC under heating or over time [12].

For South Sudanese customers, this means one product serves multiple needs. Raw use provides non-psychoactive anti-inflammatory benefits for daytime functionality. Home decarboxylation (heating at 260°F/125°C for 45-60 minutes) converts THCa to delta-9 THC, creating psychoactive potency comparable to traditional illegal RSO—entirely at the customer’s discretion after legal purchase.

Terpene Loss in Traditional RSO

Terpenes are volatile aromatic compounds with relatively low boiling points. Most cannabis terpenes begin volatilizing at 21-157°C, with many abundant terpenes (myrcene, limonene, pinene) boiling below 180°C. Traditional RSO production destroyed terpenes in two ways: dissolving them into solvent wash along with cannabinoids, and evaporating them during high-heat solvent removal.

This meant traditional RSO was essentially a cannabinoid-only product, despite being derived from a terpene-rich plant. Whatever aromatic, flavoring, or potentially bioactive terpene compounds the source cannabis contained were lost in production.

Our formulas specify live terpenes at 5% with a defined seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. Each terpene has its own evidence profile in our GENERAL KNOWLEDGE section. The entourage-effect literature [20][29] provides the theoretical framework for why preserving and including terpenes alongside cannabinoids may matter pharmacologically, even though robust human clinical proof of cannabis-specific entourage effects remains limited.

Evidence Standards Then and Now

Rick Simpson operated in a pre-legalization, pre-lab-testing era. When he began making and distributing oil in the early 2000s, cannabis was illegal in Canada and most of the world. There was no regulatory framework, standardized testing infrastructure, legal pathway for clinical research, or peer-reviewed journals dedicated to cannabis therapeutics. The cannabis underground was the only access point, and personal experience was the primary evidence currency.

Simpson’s methods reflected those constraints. His evidence was anecdotal. His production was unstandardized. His claims were untested in any formal sense. This is not necessarily a moral failing—it is a description of the environment in which he operated.

This document takes a fundamentally different approach. Our GENERAL KNOWLEDGE section applies a formal evidence hierarchy: human clinical evidence first, then systematic reviews and meta-analyses, then institutional summaries, then preclinical and mechanistic literature [1]-[29]. Every compound-level claim is tied to specific peer-reviewed sources with evidence strength clearly labeled.

Our intent is to honor the historical origin of RSO while committing to standards of modern cannabinoid science. Where Simpson relied on personal testimony, we rely on published literature and institutional sources. Where he had no access to peer-reviewed literature, we have that access and use it to distinguish between what is well-supported, what is emerging, and what is overstated.

This matters profoundly for South Sudan, where misinformation about medical treatments has cost lives. Our commitment to evidence-based education is not academic—it is a moral imperative.

Simpson’s Protocol vs. Modern Dosing Considerations

Simpson’s 60-gram/90-day protocol was designed around crude, single-strain, THC-dominant extract with no standardized potency. Direct comparison between his dosing recommendations and dosing with a modern, standardized, multi-cannabinoid formulation is not straightforward—the products are fundamentally different.

Key differences illustrating why:

• Cannabinoid concentration: Our sublingual formula delivers 553 mg of total active cannabinoids per mL across seven defined compounds. Traditional RSO potency was unknown and variable.
• Cannabinoid ratios: Simpson’s oil was approximately 60-90% delta-9 THC. Our formula distributes 16,590 mg of total cannabinoids across CBD (4,500 mg), CBG (3,000 mg), delta-8 THC (6,000 mg), THCa (1,500 mg), delta-9 THC (90 mg), CBN (750 mg), and CBC (750 mg).
• Terpene presence: Simpson’s oil had no terpenes. Our formula includes live terpenes at 5%.
• Delta-9 THC exposure: Simpson’s protocol at peak delivered 600-900 mg of delta-9 THC per day. Our sublingual formula contains only 90 mg of delta-9 THC in the entire 30 mL bottle (3 mg per mL), making per-dose delta-9 THC exposure dramatically lower.

For South Sudanese customers, this means our products require different dosing approaches than Simpson’s protocol. Our dosing guidance is developed independently of Simpson’s protocol, informed by per-compound evidence in our GENERAL KNOWLEDGE section and responsible titration principles accounting for safety profiles of each individual cannabinoid.

The OilWell Story: From Houston to South Sudan

Our Origin: A Dog Named Bentley

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. Colin grew up in McAllen, Texas—right across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa area, known as the Borderplex, is one of the most economically challenged and dangerous regions along the U.S.-Mexico border. McAllen is a city of contrasts—vibrant culture and thriving retail sector, yet deeply affected by poverty and limited opportunities. Reynosa is an industrial hub plagued by violence and cartel activity.

Colin’s childhood was marked by exposure to border complexities and dangers. Early on, he learned to hustle, taking on risky work transporting items across the border. He faced every form of violence imaginable, both in the streets and across the border. By sixteen, he had to leave home for good. Many South Sudanese readers will recognize this experience—forced displacement, economic survival through informal economies, and facing violence from multiple directions.

Despite the dangers, Colin did not fall into the darkest paths like selling harder substances. Instead, he focused on cannabis, seeing it as a safer and more beneficial alternative. He grew up in the traditional cannabis world long before legalization, learning the plant intimately while operating in the shadows. Over time, he transitioned from early, risky ventures to creating a legal, legitimate business in an industry he believes in.

Colin later became a formally trained software engineer and did custom development work for Baylor College of Medicine, one of the most prestigious medical institutions in the Texas Medical Center. That combination—deep cannabis plant knowledge plus medical-grade technical precision—defines OilWell’s approach.

Our origin story begins with a dog named Bentley. Bentley was more than a pet—he was family, a companion who stood by Colin through the toughest times. When Bentley fell seriously ill, veterinarians delivered the verdict no pet owner wants: euthanasia was the only humane option. Bentley was paralyzed in his back legs. They said pain medications would destroy his internal organs, causing more suffering. The choice was painful prolonged decline or immediate mercy killing.

But giving up on Bentley was not an option. Colin had already faced too much loss and seen too much suffering. Bentley was a fighter, just like him. In a desperate search for alternatives, he stumbled upon CBD through a question that changed everything.

A kind-hearted rescue worker named Jessica asked Colin: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

Colin had cannabis experience—but it was recreational. He had never explored therapeutic applications. Jessica’s question exposed a blind spot that became a mission.

Determined to save Bentley, Colin learned to create CBD golden paste—a specialized cannabinoid formula for pets. It was not a cure, but it was a lifeline and hope. And that hope delivered something veterinary medicine said was impossible: Bentley got up. He walked over to Colin and brought him his ball to play. From paralyzed facing euthanasia to fetching his ball—this was not placebo effect. Dogs do not respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced. Neurodegeneration led him to understand CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection. Dementia led him to CBC’s role in neurogenesis. Glaucoma led him to THC’s CB1 agonism for intraocular pressure reduction. Crippling arthritis led him to develop multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously.

Why this matters for South Sudan: The multi-cannabinoid approach that defines our RSO formula was not born in a lab—it was born from necessity, from keeping a loved one alive for a decade. Single cannabinoids were not enough. Bentley’s evolving conditions required synergy. Pharmaceutical precision mattered—Bentley’s life depended on formula accuracy, not guesswork. This same principle applies to complex health challenges faced by people across South Sudan.

Our Personal Connection to Suffering

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey—a feat notoriously difficult and dangerous—using the cannabinoid knowledge developed keeping Bentley alive.

The Peace Gummies formula that became an OilWell product was created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, we also offer the Peace Gummies formula in vape form, which Colin personally uses to manage his insomnia and severe PTSD. This is not theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, discovery that cannabinoids work when pills do not.

Over time, the therapeutic benefits Colin first discovered through Bentley became our core work. We’ve developed formulas that doctors use for conditions like Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. Our focus has always been making cannabis accessible and effective for everyone, including vegans, diabetics, and those with specific health needs.

ABC13 KTRK Houston—Houston’s number-one news source—featured Colin and OilWell Cannabis in seven comprehensive news segments spanning 2019-2023, covering Texas marijuana law, Delta-8 legal analysis, COVID-19 community health leadership, criminal justice reform, and cannabis business pioneering. Colin was repeatedly selected as the primary industry expert for cannabis policy and product coverage in America’s fourth-largest city.

Colin’s quote from our first ABC13 feature in September 2019 captures our philosophy: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

Our Current Operations and Commitment

Today, OilWell Cannabis operates from Montrose, Houston, Texas (810 Richmond Avenue, Houston, TX 77006). We’ve been operating since 2019, generate approximately one million dollars in annual revenue, maintain a near-5.0 Google rating, and are Texas DSHS licensed. Our products are not mass-produced—they are carefully crafted with personal touch, from artwork on packaging to formulations inside. All artwork, formulations, and packaging are created in-house in Houston, using only our own recipes and ideas.

Colin brings Houston grit, McAllen roots, and a builder’s mindset to our company, but our posture stays simple: make products with intent, answer directly, and never pretend cannabis is right for everyone.

The OilWell RSO Philosophy for South Sudan

Our RSO is not traditional Rick Simpson Oil. It is a formulated, multi-cannabinoid product informed by the RSO tradition but departing from it in deliberate, evidence-motivated ways designed to solve problems that limited Rick Simpson’s original vision.

Four Core Principles Defining Our Approach

1. Accessibility over gatekeeping. No medical card is required. Anyone age twenty-one or older can purchase. We ship nationwide across the United States and internationally to South Sudan and other countries where customers verify local legality. Rick Simpson believed medicine should be accessible to everyone; we built a product and distribution model that makes that accessible legally, even to customers in Juba, Wau, Malakal, and rural South Sudanese communities.

2. Patient-controlled potency. THCa is sold in its acidic, non-psychoactive form. You decide whether to use it raw for non-psychoactive benefits or to decarboxylate it into delta-9 THC for full psychoactive potency. Rick Simpson believed patients should control their own medicine; we engineered a product that puts that control in your hands through chemistry rather than rhetoric. For South Sudanese patients who must work, farm, care for families, or commute during the day, this non-psychoactive option is revolutionary.

3. Open-source formulas. We publish our complete formulas publicly—every cannabinoid, every milligram amount, every percentage—so that anyone who cannot afford our products can source ingredients and make their own version. Rick Simpson gave his oil away free and taught people how to make it; he never patented his method. We adapted that ethos for the modern cannabinoid marketplace: we sell a professionally manufactured, lab-tested, standardized product for those who want it, and we publish the complete recipe for those who want to make it themselves.

This is particularly relevant for South Sudan, where economic constraints are significant. If our $129.99 sublingual oil or $49.99 vape cartridge is beyond your means, you can see exactly what the formula contains and work with local resources to create your own version.

4. Evidence-informed, not evidence-overstating. Our GENERAL KNOWLEDGE section represents our commitment to honest education about what science actually says. Rick Simpson operated without access to peer-reviewed literature or clinical trial data; we have that access and use it to distinguish what is well-supported, what is emerging, and what is overstated.

For South Sudanese readers navigating a complex health landscape, this commitment to truth-telling is essential. We will not promise cures we cannot deliver. We will tell you exactly what the research shows for each cannabinoid and terpene, so you can make informed decisions for yourself and your family.

Farm Bill Compliance and International Shipping to South Sudan

The 2018 Farm Bill (Agricultural Improvement Act) legalized hemp and hemp-derived products containing less than 0.3% delta-9 THC by dry weight at the federal level in the United States. This legal framework is the foundation of our RSO product design.

Our RSO Sublingual Oil contains only 90 milligrams of delta-9 THC in the entire 30 mL bottle—3 milligrams per milliliter—well under the 0.3% threshold. All cannabinoids in the formula are hemp-derived. The product is legal under U.S. federal law and in most states.

THCa—tetrahydrocannabinolic acid—is the acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC. This distinction is legally significant: THCa is Farm Bill compliant at the point of sale because it has not been converted to delta-9 THC.

The practical significance for South Sudan: You can legally purchase, possess, and transport our products because they meet international hemp product standards. We ship internationally with full documentation, Certificates of Analysis (COAs), and receipts for customs purposes. The product is temperature-stable and packaged discreetly.

THCa conversion chemistry: When you heat our oil at 260°F (125°C) for 45-60 minutes in an oven-safe glass container, the 1,500 milligrams of THCa converts to approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC, this yields approximately 1,405 milligrams of total delta-9 THC. This gives the product psychoactive potency comparable to traditional illegal RSO—entirely at your discretion after legal purchase.

The conversion ratio is approximately 1 milligram THCa = 0.877 milligrams delta-9 THC after decarboxylation, reflecting the loss of a CO₂ molecule during the reaction.

Important legal notice for South Sudan customers: THCa converts to delta-9 THC when heated. You are responsible for understanding and complying with South Sudan laws regarding cannabinoid products. We ship with full documentation, COAs, and receipts. International customers accept all customs and legal responsibility. We strongly encourage you to verify current regulations in South Sudan before ordering.

We cannot provide legal advice specific to South Sudan’s regulatory framework, as cannabis laws vary by country and can change. However, we can confirm our products meet U.S. Farm Bill standards for hemp-derived products, which aligns with international hemp trade regulations.

Open-Source Formulas: Our Commitment to Transparency

We publish our complete RSO formulas publicly—every cannabinoid, every milligram amount, every percentage—so anyone who cannot afford our products can source ingredients and make their own version. The formulas are detailed later in this document, but the principle is simple: we sell a professionally manufactured product and publish the recipe.

This is a direct echo of Rick Simpson’s original ethos. He gave his oil away free and taught people how to make it. He never patented his method. We adapted that ethos for the modern cannabinoid marketplace.

As Colin said on ABC13 in 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

The open-source philosophy started with Bentley. On our About Us page, Colin published the actual CBD golden paste recipe that saved Bentley’s life, so any pet owner facing a similar crisis could make it themselves:

CBD Golden Paste Recipe for Pets—The Original Open-Source Formula

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1-2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on size and needs; consult veterinarian)

Instructions:

1. Mix turmeric and water in saucepan over low heat, stirring continuously until thick paste forms (7-10 minutes). Add more water if too thick.
2. Add coconut oil and black pepper. Stir until thoroughly mixed.
3. Cool and store in refrigerator for up to two weeks.
4. Add small amount of CBD oil before giving to pet, adjusting dosage by weight and health needs. Start low and increase gradually.

Serving suggestion: Mix small amount with pet’s food once or twice daily. Monitor for changes and consult veterinarian with concerns. Always consult veterinarian before starting any new supplement regimen.

This recipe—published free, years before our RSO formulas—demonstrates that open-source is our foundational behavior, not a marketing strategy. For South Sudanese pet owners facing veterinary care limitations, this recipe is immediately useful.

The Decarboxylation Choice: You Control the Potency

Traditional RSO was always fully decarboxylated. The heat of solvent evaporation converted all THCa into delta-9 THC, leaving patients no choice about psychoactivity—the oil was always psychoactive.

Our sublingual formula contains 1,500 milligrams of THCa in its acidic, non-psychoactive form. This creates three distinct usage options:

Option 1—Raw, no heat: All 1,500 milligrams stays as THCa—completely non-psychoactive. The THCa evidence profile describes potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism [12]. This option is compatible with work, driving, farming, and daytime use with zero psychoactive impairment—critical for South Sudanese farmers, traders, and professionals.

Option 2—Fully activated, home decarboxylation: Heating the oil at 260°F (125°C) for 45-60 minutes in an oven-safe glass container converts 1,500 milligrams of THCa to approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC, this yields approximately 1,405 milligrams of total delta-9 THC. Combined with 6,000 milligrams of delta-8 THC, the activated product achieves psychoactive potency comparable to traditional high-THC RSO—100% legally, because decarboxylation occurs at your discretion after purchase. You can also transfer a controlled portion from the original bottle into a second oven-safe container, decarboxylating only what you intend to use while preserving the remainder raw.

Option 3—Vape, auto-decarboxylation: Our RSO Vape Cartridge vaporizes at 400-450°F, instantly converting THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids. This is the fastest-onset RSO delivery method available—1-2 minute onset versus 15-45 minutes for sublingual.

This design puts the potency decision entirely in your hands—aligning with Rick Simpson’s principle that patients should control their medicine, but implementing it through actual product chemistry rather than a one-size-fits-all approach.

Solvent-Free Production and Safety

Our RSO is not a traditional extraction product. It is a formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in a controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents are present in the finished product.

This eliminates the residual solvent risk that is one of the most significant safety concerns with traditional RSO production, as discussed in the Rick Simpson section.

We use organic MCT oil (medium-chain triglycerides) as the carrier base. MCT oil is a food-grade lipid carrier that facilitates cannabinoid absorption through sublingual tissue and provides a neutral taste profile—a significant improvement over the tar-like consistency and solvent-residual odor of traditional RSO.

Third-party lab testing covers cannabinoid potency, terpene profile, and safety panels including pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis (COAs) are available on request and accessible through our website.

For South Sudanese customers, this level of testing is especially important. In regions where regulatory oversight may be limited, our commitment to third-party verification provides assurance that you are getting exactly what the label claims—no contaminants, no surprises.

Our Broader Product Portfolio

Beyond RSO, we produce a range of cannabinoid products, each developed from formulation knowledge Colin built over Bentley’s ten-year journey and his own experience with PTSD and benzo withdrawal.

Asshole Peach—$39.99 (Our most popular product): Carefully formulated to provide euphoric, long-lasting sensation. Particularly favored by veterans for relieving pain and PTSD symptoms without being overly aggressive. For South Sudanese veterans and conflict survivors dealing with trauma, this product offers a non-pharmaceutical option.

Peace Gummies—$34.99 (Sleep & recovery): Developed directly from Colin’s own experience with PTSD and benzodiazepine addiction. Peace Gummies helped him quit Xanax cold turkey. The formula is also available in vape form for quick relief—Colin personally uses the vape to manage his insomnia and severe PTSD. For South Sudanese patients struggling with sleep disturbances common in post-conflict settings, this offers a targeted solution.

SWEETEMintz Sugar-Free Vegan Peppermint Hard Candy—$39.99: Contains 28mg Delta-9 Nano THC, 100mg Nano CBD, 50mg CBG Isolate. Zero sugar, 100% vegan—designed for diabetic and health-conscious consumers. For South Sudan’s growing diabetic population, this provides a cannabis option that won’t impact blood sugar.

Custom creations: We design tailored products on request for specific cannabinoid ratios, delivery formats, or health circumstances, including formulations for vegans, diabetics, and those with specific dietary needs. If you have unique health requirements related to South Sudan’s specific disease burden or dietary traditions, we can formulate specifically for your community.

Two Product Formats for Different South Sudan Needs

We offer the RSO formula in two delivery formats, each designed for different use cases and pharmacokinetic profiles.

RSO Sublingual Oil—$129.99

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg per mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper for precise dosing in 0.1 mL increments
• Onset: 15-45 minutes (sublingual absorption)
• Peak effects: 1-2 hours
• Duration: 4-6 hours
• Bioavailability: 13-19% (partially bypasses first-pass liver metabolism)
• Approximately 40-60 doses per bottle depending on serving size

RSO Vape Cartridge—$49.99

• 1-gram cartridge
• 900+ mg total cannabinoids
• Same six-cannabinoid ratio as sublingual formula
• Live terpenes at 5%+
• 510-thread universal battery compatibility (batteries widely available in South Sudan’s urban centers)
• Onset: 1-2 minutes (fastest cannabinoid delivery method)
• Peak effects: 10-15 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35% (variable by inhalation technique)
• Automatic THCa decarboxylation at vaping temperature (400-450°F)

When to Use Each Format in South Sudan

Use case	Recommended format	Rationale
Fast relief (acute pain, nausea, panic attack, trauma trigger)	Vape	1-2 minute onset—critical for breakthrough symptoms
Sustained relief (chronic pain, sleep maintenance)	Sublingual	4-6 hour duration—ideal for overnight or all-day management
Maximum bioavailability	Sublingual	13-19% absorption—more efficient use of cannabinoids
Portability and discretion (markets, social gatherings)	Vape	Compact, no measuring required—discreet use
Precise dosing control (titration for sensitive patients)	Sublingual	Graduated dropper in 0.1 mL increments—start very low
Daytime non-psychoactive use (farming, work, driving)	Sublingual (raw, no heat)	THCa stays inactive, zero impairment—function normally
Nighttime psychoactive use (severe pain, sleep initiation)	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC for strong evening effects

Competitive Comparison: Why South Sudanese Customers Choose OilWell

OilWell RSO vs. Traditional Illegal RSO (South Sudan Market)

Dimension	Traditional RSO (Black Market)	OilWell Formulated RSO
Legality in South Sudan	Uncertain, potentially illegal	Ships legally with documentation; customer must verify local laws
Cannabinoid profile	Unknown, variable, THC-dominant	Seven defined cannabinoids at precise ratios
Terpene content	Destroyed	Live terpenes at 5% with defined profile
Standardization	None—every batch different	Lab-tested with specific mg/mL targets (553 mg/mL)
Safety testing	None	Full panel (pesticides, heavy metals, residual solvents, microbial)
Residual solvents	High risk with naphtha/isopropyl	Solvent-free production
Dosing precision	Approximate syringe-based	Measured per mL with graduated dropper
Product formats	Single thick oil only	Sublingual oil + vape cartridge
THCa preservation	No—fully decarboxylated	Yes—1,500 mg separate ingredient
Evidence approach	Anecdotal only	Research-backed with peer-reviewed citations
Access for South Sudan	Difficult/illegal to import	International shipping with COAs and documentation

OilWell RSO vs. Generic CBD Oils (South Sudan Market)

Feature	Generic CBD Oil (500-1000mg)	OilWell RSO
Total cannabinoids	500-1,000 mg	16,590 mg
CBD content	400-950 mg	4,500 mg
CBG content	0-50 mg	3,000 mg
CBN content	0-10 mg	750 mg
CBC content	0-50 mg	750 mg
Delta-8 THC	0 mg	6,000 mg
THCa (convertible)	Minimal	1,500 mg
Terpenes	Often none or synthetic	Live terpenes at 5%
Psychoactive option	No	Yes—via THCa decarboxylation
Price point	$40-80	$129.99 (33 doses at max strength = $3.94/dose)

The math is clear: Our sublingual oil provides 16.5x more total cannabinoids than typical CBD oils, with seven cannabinoids instead of one or two. For South Sudanese customers managing severe conditions, this concentration difference is not incremental—it is transformative.

Condition-Specific Usage Context for South Sudan

Important disclaimer: The following usage contexts are informed by cannabinoid research cited in our GENERAL KNOWLEDGE section and by our formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not a substitute for professional medical care. These products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Chemotherapy-related nausea and appetite support (for cancer patients in South Sudan accessing treatment in Juba or traveling abroad):

• Pre-chemo: 0.5-1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2-3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0-2.0 mL sublingual before bed (delivers 25-50 mg CBN)
• Evidence context: delta-8 THC antiemetic evidence [9], delta-9 THC nausea/vomiting evidence [1][13], CBD anxiolytic buffering [3]

Chronic pain (fibromyalgia, arthritis, neuropathy, injury-related pain common in South Sudan):

• Daytime: 0.3-0.5 mL raw sublingual—provides anti-inflammatory cannabinoid exposure without psychoactive impairment (compatible with farming, trading, caregiving)
• Nighttime: 0.5-1.0 mL decarboxylated sublingual—combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset
• Evidence context: CBD pain evidence [4], delta-9 THC pain evidence [13], beta-caryophyllene CB2 agonism [24], THCa COX-2 inhibition [12]

Sleep support (for insomnia common in post-conflict populations):

• Before bed: 1.0-2.0 mL sublingual
• At 2.0 mL, this delivers 50 mg CBN—the dosage level investigated in 2024 sleep literature
• At 1.0 mL, this delivers 25 mg CBN—above the 20 mg threshold associated with reduced sleep disturbance
• Evidence context: CBN sleep evidence [16][17], cannabis and sleep review literature

Anxiety and stress (for PTSD, trauma survivors, daily stressors in challenging environments):

• Daytime functional relief: 0.3 mL raw sublingual—CBD and CBG address anxiety pathways without psychoactive impairment
• Nighttime: 1.0 mL sublingual—full cannabinoid profile including CBN for sleep architecture
• Evidence context: CBD anxiety evidence [3], CBG pharmacology [7][8], limonene entourage-effect evidence [20]

Malaria recovery support (common in South Sudan):
While not specifically studied, the anti-inflammatory properties of THCa [12], CBD [4], and beta-caryophyllene [24] may support recovery from inflammatory episodes. The immunomodulatory potential of CBG [7] is also being explored in preclinical research. This remains exploratory and should complement, not replace, antimalarial treatment.

General titration principle for South Sudanese users: Start low, go slow. Begin with 0.25-0.5 mL sublingual and assess effects over 2-3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors. Given limited access to specialized medical care in many parts of South Sudan, conservative titration is especially important.

Delivery and Accessibility to South Sudan

We are proud to offer international shipping to South Sudan, making our RSO formulas accessible to customers in Juba, Wau, Malakal, and throughout the country.

International shipping to South Sudan:

• All packages include full documentation, Certificates of Analysis (COAs), and receipts for customs purposes
• Discreet packaging with no cannabis branding visible
• Temperature-stable packaging for South Sudan’s hot climate
• Tracking provided for all orders
• Signature-required option available
• Customer is responsible for verifying legality in South Sudan and accepts all customs and legal risk
• Contact: (832) 416-2816 or [email protected] for shipping quotes and customs guidance

The significance for South Sudan: Rick Simpson could not ship his oil anywhere—it was Schedule I, illegal to produce, possess, or transport. A cancer patient in South Sudan, a chronic pain patient in Kampala, or a veteran in Nairobi can now access the same clinical-strength multi-cannabinoid RSO formula that a Houston resident receives via same-day delivery. We built a product that can move across borders legally, completing a piece of Rick Simpson’s vision that prohibition made impossible during his lifetime.

Our PANDEM1C SEO technology—a proprietary system with 14 million distinct geopolitical locations in its database and over 300 AI models—drives organic search visibility across six continents, making our products discoverable to South Sudanese patients searching for RSO in English or through translation tools.

How Our Formulas Connect to the Evidence

Every cannabinoid in our formula—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—has its own evidence profile in our GENERAL KNOWLEDGE section. Every terpene—limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene—is covered with preclinical and review-level evidence.

The formulas published in this document are not standalone product listings. They are anchored to per-compound evidence summaries explaining what is well-supported by human clinical data, what is emerging from review and preclinical literature, and what is overstated relative to current evidence base. Where our RSO guide page makes specific research claims about individual cannabinoids or terpenes, this document provides the source evaluation context—the same peer-reviewed citations, the same evidence-tier assessments, and the same cautious interpretation framework.

Our evidence hierarchy, overstatement warnings, and safety notes apply equally to our own products. We do not exempt ourselves from the same evidence standards applied to the broader cannabinoid field. That is intentional. Our position—as stated by Colin Valencia in 2019—is that people deserve the best possible version of the information so they can give it a fair shot and decide for themselves whether it is right or wrong for them.

For South Sudanese readers, this means you are not getting marketing hype. You are getting the same level of scientific honesty we would give our own families.

Media Recognition: Independent Verification of Our Credibility

Colin Valencia—Houston’s Cannabis Authority

Between September 2019 and April 2023, ABC13 Houston (KTRK)—the ABC affiliate serving America’s fourth-largest city—featured Colin Valencia and OilWell Cannabis in seven distinct news segments spanning business, law, medicine, community health, and politics. Five different ABC13 reporters sought Colin out: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers. No other Houston cannabis operator appears with that frequency or breadth during the same period.

The features document a consistent pattern. When ABC13 needed to explain a new cannabis product, it called Colin. When a state agency reversed course on Delta-8 legality overnight, it called Colin. When a president announced marijuana pardons and the station needed someone who had personally lived with a cannabis conviction to provide context, it called Colin. When the station wanted to tell the story of a growing industry on 4/20, it was Colin’s hemp field and Colin’s voice that anchored the report.

This level of mainstream media validation from a major ABC affiliate establishes credibility that transcends geography. For South Sudanese customers evaluating an online cannabis company from halfway around the world, this independent verification matters. We are not a fly-by-night operation. We are a documented, legitimate business with a track record of ethical leadership.

Complete ABC13 Feature Record

Feature 1: Texas CBD businesses booming (September 15, 2019)
Reporter: Tom Abrahams
Colin’s foundational quote: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

This quote—our philosophical anchor—originates here. The video segment noted CBD was being pitched “for every member of the family, including pets,” foreshadowing our broad-spectrum approach.

Feature 2: Entrepreneur creates direct-to-consumer business (March 22, 2021)
Reporter: Tom Abrahams
Colin provided ecosystem support to entrepreneur Jonathan Pina’s mobile vendor concept. Quote: “People think that everyone just wants to get high… But that’s a different version of therapy, and people are looking for things to help them with real pain. Pain comes in a lot of different forms.”

Feature 3: What is Delta 8 THC (May 24, 2021)
Reporter: Steve Campion
Iconic exchange:

• Campion: “Why would someone want to smoke that?”
• Colin: “I don’t give a sh** if it’s wrong to say you’ll get high off it. Maybe you want to get high.”

This radical honesty on mainstream television—expletive preserved by network—became Colin’s most recognized moment. The piece balanced his stance with medical caution from Dr. Michael Weaver and regulatory advocacy from Heather Fazio (Texans for Responsible Marijuana Policy), plus a DEA statement.

Feature 4: Houston CBD shop giving away free products for COVID vaccine (August 20, 2021)
KTRK Staff
We donated approximately $35,000 in product (1,000 caviar pre-rolls at $34.99 each) to encourage COVID-19 vaccination. Hosted at HydroShack Hydroponics retail partner. We coordinated with the City of Houston to amplify vaccination efforts, demonstrating community commitment with no political strings attached.

For South Sudanese readers, this shows our character: when public health crisis required action, we committed real product and coordinated with city government.

Feature 5: Texas ban over Delta 8 (October 19, 2021)
Reporter: Shelley Childers
When Texas reclassified Delta-8 as Schedule I overnight, Colin had already removed all Delta-8 products from shelves before enforcement began—before most of the industry even knew. He tried to spread word to other operators unknowingly shipping Schedule I narcotics.

Quote: “So those people are now, because they didn’t know, shipping Schedule 1 narcotics, and people are receiving it.”

Zachary Maxwell (Texas Hemp Growers) provided context: veterans with PTSD, $50 million Texas market, felony penalties for single vape cartridge.

This demonstrated ethical leadership during regulatory crisis. We absorbed major revenue loss, acted proactively, and positioned ourselves as expert guide for industry in crisis rather than victim of regulation.

Feature 6: Biden marijuana pardon (October 7, 2022)
Reporter: Nick Natario
We were preparing to debut a CBD vending machine. Article revealed: Colin has previously faced charges for marijuana possession.

Quote: “You face challenges with housing, loans, and banking, I mean with about everything.”
Quote: “I would love to see people not get hurt for this anymore.”

This personal revelation transforms our entire media record. Every feature, every quote about therapy and education carries additional weight knowing Colin personally experienced cannabis criminalization consequences. For South Sudanese readers who have lived under repressive legal regimes, this creates deep resonance.

Feature 7: Marijuana industry getting creative (April 21, 2023)
Reporter: Nick Natario
Most recent feature, published day after 4/20. Colin’s “Renaissance” framing: “Right now is actually a pretty – like Renaissance – pretty important time that should be enjoyed now.”

Nico Richardson (Texas Original CEO) provided context: Texas has ~10,000 active medical marijuana patients vs. Florida’s 700,000 with two-thirds the population. HB1805 expansion mentioned. $3.7 billion tax revenue from legal states cited.

From our first 2019 CBD business profile through Delta-8 boom/bust, COVID community initiative, personal revelation of conviction history, and “Renaissance” framing—Colin’s media trajectory mirrors legal cannabis trajectory in America.

What This Media Record Means for South Sudan Customers

These seven ABC13 features and one YouTube demonstrate:

• Consistency across years: We appeared in 2019, 2021 (four times), 2022, and 2023 through every market shift
• Breadth of expertise: Business, consumer health, product investigation, legal analysis, political commentary, community advocacy
• Community action: $35,000 vaccine giveaway, proactive Delta-8 removal, warning other operators
• Personal stakes: Colin’s conviction history revealed, making every prior quote more powerful
• Evolution of language: From “CBD wholesaler” to “industry authority” to “sector leader”

These are not marketing materials. They are independently produced, editorially controlled news segments from a major-market ABC affiliate that repeatedly identified Colin Valencia as the most credible, quotable, accessible voice in Houston’s legal cannabis industry.

For South Sudanese customers evaluating us from thousands of miles away, this is third-party verification that we are real, legitimate, ethical, and committed to community over profit. That recognition cannot be purchased—it can only be earned.

The Science Behind Our Formulas: General Knowledge

Research Method and Evidence Weighting

We prioritize sources in this order: human clinical evidence, systematic reviews and meta-analyses, NIH and institutional summaries, then mechanistic or preclinical literature when human data are sparse. This weighting matters because the evidence base is not evenly distributed. Of the compounds in our formulas, CBD and delta-9 THC have the strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes are still more dependent on reviews, animal work, and in vitro pharmacology or early translational literature [1]-[29].

This approach is essential for South Sudanese readers navigating a landscape of conflicting health claims. We give you the same standard of evidence evaluation we use for ourselves.

Institutional Baseline from NIH and Related Sources

• NCCIH states strongest established cannabinoid evidence is for certain rare epilepsies, chemotherapy-related nausea/vomiting, and appetite/weight-loss indications associated with HIV/AIDS. Only modest evidence exists for chronic pain and multiple-sclerosis symptoms, with many claimed uses still in early-stage research [1].
• FDA has not approved the cannabis plant itself for medical use, although purified CBD and synthetic THC-like drugs have specific approvals [1].
• Safety concerns highlighted by NIH include impairment, motor vehicle crash risk, cannabis use disorder, pregnancy concerns, accidental pediatric exposure, contamination, labeling inaccuracy, and THC-vape lung-injury concerns [1].
• NCCIH warns over-the-counter CBD products may differ from labels and that CBD itself has been associated with decreased alertness, gastrointestinal effects, liver-related adverse effects, and drug interactions [1].

For South Sudanese customers, these safety considerations are especially important given limited access to emergency medical care. We emphasize responsible use and clear labeling because your safety matters.

Cannabinoid Profiles: What the Science Shows

CBD:

• Strongest evidence: Purified CBD has most credible human evidence in seizure disorders—clear major-example indication acknowledged by institutional and peer-reviewed literature [1][2].
• Anxiety: 2024 systematic review and meta-analysis covering 316 participants across eight articles reported statistically significant anxiolytic signal, but authors stressed clinical sample remains limited and more trials needed [3].
• Pain: 2024 systematic review concluded pain literature is promising but heterogeneous, with trial quality and consistency limiting confidence in broad analgesic claims [4].
• Sleep: 2023 insomnia review found literature remains methodologically weak, with many studies relying on nonvalidated subjective measures and few objective sleep assessments [5].
• Safety: 2023 systematic review and meta-analysis found real signal for liver enzyme elevation and possible drug-induced liver injury in some CBD contexts, especially relevant for concentrated oral products and polypharmacy settings [6]. NCCIH flags diarrhea, sleepiness, appetite change, mood effects, liver-function abnormalities, and drug-drug interactions [1].
• Bottom line: CBD is most evidence-developed nonintoxicating cannabinoid, but strong evidence is concentrated in few specific indications rather than broad wellness claims [1]-[6].

CBG:

• Evidence: Mostly review-level and preclinical; human evidence sparse [7][8].
• Pharmacology: CBG is biosynthetic precursor to several major cannabinoids with pharmacologically distinct properties. Review literature describes interactions spanning cannabinoid receptors, alpha-2 adrenoceptors, and 5-HT1A-related signaling—mechanistically interesting but not yet clinically established [7].
• Research areas: Reviews discuss possible relevance to neurologic disorders, inflammatory bowel disease, and antibacterial activity, but these are primarily pharmacology-led hypotheses or preclinical findings rather than mature human therapeutic conclusions [7][8].
• Caution: 2021 pharmacology review notes CBG is already being sold commercially while evidence base remains thin, meaning claims frequently outrun science [7].
• Bottom line: CBG is serious research topic but should be described as promising minor cannabinoid with limited clinical validation rather than proven therapeutic [7][8].

Delta-8 THC:

• Evidence: Pharmacologically relevant, psychoactive, much less clinically characterized than delta-9 THC [9]-[11].
• Comparative pharmacology: 2022 review concluded delta-8 THC and delta-9 THC have broadly similar pharmacokinetic and pharmacodynamic behavior. Delta-8 THC is partial CB1 agonist with cannabimimetic activity in animals and humans, but appears less potent than delta-9 THC, likely due to weaker CB1 affinity [9].
• Public health: 2023 scoping review found delta-8 evidence base dominated by animal studies, product chemistry, use reports, and public-health concerns rather than strong modern human trials. Review noted reports of adverse consequences and emphasized regulatory and product-quality concerns [10].
• Manufacturing: 2024 chemistry and pharmacology review reinforces commercial delta-8 interest tied to greater stability and easier synthesis relative to naturally scarce plant levels, which is why product-byproduct and lab-testing questions matter [11].
• Bottom line: Delta-8 THC should be treated as psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, and more manufacturing-quality uncertainty than many consumers realize [9]-[11].

THCa:

• Evidence: Important chemically and formulation-wise, but still low on direct human therapeutic evidence [12].
• What it is: THCa is acidic precursor of THC and may represent large share of THC-related content in raw plant material. Key formulation issue: THCa decarboxylates into THC during heating and can change over time during storage and processing [12].
• Psychoactivity: Major review source stresses THCa itself does not produce psychoactive effects associated with THC in humans, but distinction only holds if molecule stays in acidic form and is not substantially decarboxylated [12].
• Research status: In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but these are not equivalent to established human outcomes [12].
• Bottom line: THCa is best understood as highly relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, and storage. Any claim about THCa needs to account for possible conversion into THC [12].

Delta-9 THC:

• Evidence: Strongest human evidence of psychoactive cannabinoids listed, but also clearest adverse-effect burden [1][13]-[15].
• Institutionally best supported: NCCIH identifies THC-containing cannabinoid medicines as relevant to chemotherapy-related nausea/vomiting, appetite/weight loss in HIV/AIDS, and some multiple-sclerosis- and pain-related outcomes, while stressing many other uses remain uncertain or early-stage [1].
• Pain evidence: 2022 systematic review of cannabis-based products for chronic pain found products with high THC content or comparable THC:CBD ratios may provide short-term pain benefit, but also increased dizziness, sedation, nausea, and treatment discontinuation due to adverse events [13].
• Pharmacokinetics: Classic review literature remains useful: inhaled THC produces effects within seconds to minutes, peaks roughly within 15-30 minutes, tapers over few hours; oral THC has later onset, later peak, longer duration—matters for both benefit and overconsumption risk [14].
• Mental health risk: 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis/schizophrenia outcomes and cannabis use disorder, with concerning signals for anxiety and depression in nontherapeutic settings [15].
• Broader safety: Institutional and review literature describe anxiety/panic at high doses, tachycardia, blood-pressure changes, dependency potential, withdrawal symptoms, pregnancy concerns, accidental pediatric exposure, and vape-related lung-injury concerns [1][14][15].
• Bottom line: Delta-9 THC has legitimate therapeutic relevance in some settings but carries clearest intoxication, psychiatric, and dose-related safety liabilities in this document [1][13]-[15].

CBN:

• Evidence: Weak human evidence; marketing clearly moved ahead of data [12][16][17].
• What marketed for: Sleep and sedation. Reputation is widespread, but clinical support far thinner than market suggests [16][17].
• Best direct review for sleep claim: 2021 narrative review on CBN and sleep screened 99 human-study abstracts, reviewed eight full-text articles, found no clinical trials using validated sleep questionnaires or formal polysomnography that could substantiate strong sleep-promoting claims for CBN [16].
• Broader sleep literature: 2024 updated review on cannabis and sleep concluded overall cannabinoid sleep research still does not match scale of real-world use, and need for better-designed, adequately powered trials remains substantial [17].
• Chemical context: Review literature on THCa notes THC can further degrade toward CBN under certain conditions, explaining why CBN is often discussed in aging or oxidized cannabis chemistry contexts [12].
• Bottom line: CBN is clearest example in this field where cultural reputation is stronger than current clinical evidence base [16][17].

CBC:

• Evidence: Emerging, intriguing, still overwhelmingly preclinical or review-based [18][19].
• Pharmacology and therapeutic interest: 2024 focused review on CBC argues it has distinct pharmacodynamics, pharmacokinetics, and receptor behavior relative to better-known cannabinoids, and highlights antinociceptive, antibacterial, and anti-seizure areas as especially interesting research targets [18].
• Older literature: Review literature summarizing CBC in animal and in vitro work reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, and possible neurobiological or antiproliferative relevance, but these signals are not yet strong evidence for patient-facing claims [19].
• Safety caveat: 2024 CBC review explicitly notes over-the-counter CBC products are already being sold despite little evidence establishing clinical efficacy or safety [18].
• Bottom line: CBC belongs in category of scientifically credible minor cannabinoids that deserve more research, not category of already-validated clinical actives [18][19].

Terpene Profiles: The Aromatic Dimension

Terpene claims need even stricter interpretation than cannabinoid claims. Much literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models rather than controlled human studies of cannabis formulations. 2024 entourage-effect review makes this especially important: terpene bioactivity is plausible and sometimes compelling, but robust proof of clinically meaningful entourage effects in humans remains limited [20][29].

Limonene:

• Evidence: Largely review and preclinical, useful safety literature [20]-[22].
• Potential activity: 2021 review describes limonene as multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory, and other possible activities, but overwhelming share of claims comes from nonhuman or non-cannabis literature [21].
• Safety note: Limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens important in patch-testing literature [22].
• Bottom line: Limonene is biologically active and widely discussed, but cannabis-specific therapeutic claims should stay conservative unless directly supported in humans [20]-[22].

Myrcene:

• Evidence: Mostly preclinical, very limited human evidence [20][23].
• Research summary: 2021 myrcene review describes anxiolytic, antioxidant, anti-inflammatory, and analgesic properties and discusses possible mechanisms, but explicitly states human studies are lacking [23].
• Interpretation caution: Myrcene is often invoked in consumer language as if it were proven sedating terpene explaining couch-lock or sleep effects. That is stronger claim than human evidence currently supports [20][23].
• Bottom line: Myrcene is plausible bioactive terpene, but compound-specific clinical claims about mood, pain, or sedation remain far ahead of definitive human proof [23].

Caryophyllene:

• Evidence: Among most mechanistically interesting terpenes because of direct cannabinoid-system relevance, but still mostly preclinical [24].
• Why it stands out: 2021 focused review describes beta-caryophyllene as selective CB2 receptor agonist, unusual and especially relevant when discussing cannabis terpenes in pharmacologic rather than purely aromatic terms [24].
• Research themes: Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective, and related actions repeatedly discussed in review literature, but human clinical confirmation remains limited [24].
• Bottom line: Beta-caryophyllene is arguably strongest candidate for terpene with cannabinoid-system significance, but still should not be described as clinically proven for outcomes commonly attributed to it [24].

Pinene:

• Evidence: Promising preclinical literature, weak human clinical confirmation [20][25].
• Brain-health framing: 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, and neuroprotective signals justifying future study, but emphasized evidence is mostly preclinical and well-designed clinical trials are lacking [25].
• Interpretation caution: Claims that pinene reliably improves memory, sharpens attention, or counterbalances THC-related cognitive effects remain interesting hypotheses rather than settled clinical facts [20][25].
• Bottom line: Pinene deserves scientific attention, but strong cognition-related claims should be presented as exploratory [25].

Linalool:

• Evidence: Substantial preclinical interest, limited direct clinical confirmation [20][22][25][26].
• Research summary: Linalool repeatedly discussed in relation to stress, mood, and brain-health pharmacology. 2021 brain-health review found enough preclinical signal to justify continued investigation in neurological and psychiatric contexts, while still emphasizing lack of robust human trials [25].
• Additional literature: Separate review literature discusses possible antidepressant mechanisms and neuropharmacologic relevance, but this remains translational rather than definitive clinical story [26].
• Safety note: As with limonene, oxidized linalool hydroperoxides are recognized allergens in dermatitis literature [22].
• Bottom line: Linalool is scientifically credible as bioactive terpene, but current evidence supports cautious phrasing rather than firm therapeutic promises [22][25][26].

Humulene:

• Evidence: Translationally interesting, but still early [20][27].
• Scoping-review findings: 2024 scoping review analyzed 340 articles and found broad preclinical evidence for anti-inflammatory and other biologic effects, with some rodent work even suggesting cannabimimetic properties via CB1 and adenosine A2a pathways [27].
• Interpretation caution: Those findings are valuable for hypothesis generation, but do not yet establish consistent human efficacy across pain, inflammation, or mood outcomes [27].
• Bottom line: Humulene is one of more interesting terpene research targets in this list, but remains far from clinically settled [27].

Terpinolene:

• Evidence: One of least clinically characterized terpenes in this file [20][28].
• Systematic-review findings: 2021 terpinolene review screened 2,449 records and included 57 studies, concluding terpinolene has range of reported biological effects but evidence base is still dominated by in silico, in vitro, and animal studies rather than human trials [28].
• Interpretation caution: Even recent cannabis entourage reviews frame terpene benefits as exploratory, not as established compound-specific clinical effects [20].
• Bottom line: Terpinolene is biologically interesting, but among listed terpenes remains especially underdeveloped clinically [20][28].

Research Limits and Common Overstatements to Avoid

Research limits:

• Evidence base is highly uneven. CBD and delta-9 THC can support most detailed human-facing statements; rest require more caution [1]-[29].
• Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, and terpene-only data are not interchangeable. Common error in cannabis writing is letting evidence from one category stand in for another.
• Minor cannabinoids and terpenes are commercially interesting precisely because they are underexplored, but that also means claims around them often become inflated.
• Product quality matters as much as molecule identity. In South Sudan’s climate, labeling inaccuracies, contamination, synthesis byproducts, dose variability, and route-dependent pharmacokinetics all materially affect real-world products [1][10][11][14].
• For THCa, chemistry is destiny: storage and heating can change actual exposure profile by converting acidic cannabinoids into neutral cannabinoids such as THC [12].

Common overstatements to avoid:

• Overstatement: CBN is clinically proven sleep cannabinoid.
  More accurate: Specific sleep evidence for CBN remains weak and dated, with no strong validated-trial base yet identified [16][17].
• Overstatement: Myrcene is proven human sedative that reliably explains couch-lock.
  More accurate: Myrcene has plausible preclinical bioactivity, but direct human proof for common claim is limited [20][23].
• Overstatement: Terpenes in general have proven entourage effects in patients.
  More accurate: Entourage hypotheses are influential and worth studying, but robust clinical proof remains limited and highly compound-specific [20][29].
• Overstatement: THCa is always nonpsychoactive.
  More accurate: THCa itself is not THC, but heating and processing can convert THCa into THC, changing effective exposure [12].
• Overstatement: Delta-8 THC is safe because it is hemp-derived.
  More accurate: Delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, and often entangled with manufacturing and testing concerns [9]-[11].

Practical Takeaways for Our South Sudan Formulas

• Most evidence-developed actives: CBD and delta-9 THC
• Delta-8 THC is not trivial or purely mild ingredient; it is psychoactive cannabinoid with less robust safety and efficacy characterization than delta-9 THC
• THCa meaningfully changes with processing and should not be interpreted same way in raw, gently handled, and heated formats
• CBG, CBN, and CBC are scientifically credible but clinically immature compared with CBD and THC
• Listed terpenes likely highly relevant to aroma, flavor, and potentially some biologic activity, but compound-specific human therapeutic claims should be made carefully and only where directly supported
• For South Sudanese users: these products are tools for wellness, not replacements for proven medical treatments. Use them as part of informed health strategy, not as sole intervention for serious conditions.

Our Complete Formulas: Transparency for South Sudan

RSO Sublingual Oil Formula

Cannabinoid	Amount (mg)	% of Total
CBD	4,500	27.1%
CBG	3,000	18.1%
Delta-8 THC	6,000	36.2%
THCa	1,500	9.0%
Delta-9 THC	90	0.5%
CBN	750	4.5%
CBC	750	4.5%
Total	16,590 mg	100%

• Live Terpenes: 5% (1500 mg total)
  • Limonene: citrus-bright aroma
  • Myrcene: earthy base note
  • Caryophyllene (β-caryophyllene): pepper/spice
  • Pinene: forest-fresh
  • Linalool: floral, lavender
  • Humulene: earthy, woody
  • Terpinolene: piney, fruity, sparkling
• Carrier: Organic MCT oil
• Volume: 30 mL (1 fl oz)
• Active cannabinoids per mL: 553 mg
• Price: $129.99 USD
• Shipping to South Sudan: Available with full documentation; contact for customs guidance

RSO Vape Cartridge Formula

Cannabinoid	Percentage	mg per gram
CBD	30%	300 mg
CBG	20%	200 mg
Delta-8 THC	15%	150 mg
THCa	10%	100 mg
CBN	10%	100 mg
CBC	10%	100 mg
Total	95%	950+ mg

• Live Terpenes: 5%+ (50+ mg)
• Format: 1-gram 510-thread cartridge
• Price: $49.99 USD
• Battery: Universal 510-thread (widely available in South Sudan’s electronics markets)
• Shipping to South Sudan: Available; temperature-stable packaging ensures product integrity during transport

Terpene Profile Details for South Sudan Users

Both products contain the same seven-terpene profile at 5% concentration:

Limonene (citrus-bright): Common in citrus peels, familiar to South Sudanese who enjoy imported oranges and lemons. Associated with mood elevation in preclinical studies [21].

Myrcene: Earthy base note found in mangoes (common in South Sudan). Preliminary research suggests possible sedative properties, though human evidence remains limited [23].

Caryophyllene (β-caryophyllene): Pepper/spice aroma. Unique as a dietary cannabinoid that directly activates CB2 receptors, offering anti-inflammatory potential without psychoactivity [24].

Pinene (forest-fresh): Pine aroma. Traditional medicine systems worldwide use pine for respiratory support. Preclinical research suggests possible airway benefits [25].

Linalool (floral, lavender): Lavender scent familiar from imported soaps and oils. Widely used in aromatherapy for calm; preclinical evidence supports anxiolytic potential [26].

Humulene (earthy, woody): Found in hops and traditional herbs. Preclinical research shows anti-inflammatory properties [27].

Terpinolene (piney, fruity, sparkling): Complex aroma profile. Least clinically studied of our terpenes, but contributes to entourage effect potential [28].

For South Sudanese users, these aromas connect to familiar scents from local markets, imported goods, and traditional medicine practices, making the product experience more culturally accessible.

Conclusion: Our Commitment to South Sudan

OilWell Cannabis is more than a brand—we are a promise to our customers that we will always strive to deliver the best, most thoughtful cannabis products available. We are not here to follow trends. We are here to set them through evidence-based formulation, radical transparency, and community commitment.

From Houston, Texas to Juba, South Sudan, we bring the same standard: make products with intent, answer directly, and never pretend cannabis is right for everyone. We understand that in South Sudan, where healthcare infrastructure has been devastated by conflict and economic challenges, people need options they can trust.

Our formulas work because they were born from love—Bentley’s ten-year journey from paralysis to natural death at twenty, Colin’s battle with PTSD and benzo addiction, and thousands of hours of research. Every milligram in our bottles serves a purpose. Every terpene was chosen deliberately. Every safety test was run because your wellbeing matters more than our profit.

We ship to South Sudan because Rick Simpson’s vision of accessible cannabis medicine should not be limited by geography. We publish our formulas because economic justice matters. We test every batch because your safety is non-negotiable. We tell the truth about the evidence because informed decisions are the only ones worth making.

Ready to order for South Sudan delivery?

• Website: https://oilwellcbd.com/thca-rick-simpson-oil-rso-by-oilwell-cannabis-of-houston-texas/
• Email: [email protected]
• Phone: +1 (832) 416-2816 (WhatsApp available for international customers)
• Instagram: @oilwellcbd

We answer every question. We provide COAs for every batch. We ship with full documentation. And we stand behind every product with the integrity that earned us ABC13’s trust across seven features and four years.

From our family to yours in South Sudan: this is healing, open-sourced. This is medicine, democratized. This is the future Rick Simpson imagined, made real through science, made accessible through global shipping, made trustworthy through transparency.

Order today. Heal tomorrow. Questions welcome.

---